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Abstract 
The economic, social, and political events that recently occurred in Egypt have exposed the 
pharmaceutical supply chain to higher levels of uncertainties and vulnerabilities, which 
makes it extremely difficult to ignore the importance of supply chain risk management. The 
aim of this research is to address pharmaceutical supply chain risks from the perspective of 
an Egyptian manufacturer, Pharco Pharmaceuticals. The main purpose is to identify and 
rank the most significant supply chain risks confronting Pharco, describe the risk 
management strategies as applied by the company, and finally, to make recommendations 
that could improve the management of supply chain risks. The research design is mainly 
qualitative in nature, and draws upon both case study and normative approaches. The 
research has identified seven types of risks at Pharco’s supply chain. It has also shown that 
external risks were perceived to be more significant than internal risks. The research has 
revealed that no clear strategy is deployed by the company to mitigate most of its supply 
chain risks. Several approaches—based on the concept of cooperation—are suggested for 
improving the management of supply chain risks. The empirical findings of this research are 
expected to enhance the company’s understanding of its supply chain risks and their 
interconnectedness, which offer valuable insights for tailoring balanced and effective risk-
reduction strategies. The findings of this research serve as a basis for a further rigorous 
research project, incorporating the identification of supply chain risks within the 
pharmaceutical industry in Egypt. 
Keywords: Pharmaceutical Supply Chain, Supply Chain Risk Management, 
Pharmaceuticals Manufacturers, Egypt. 
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1. INTRODUCTION 
In this chapter, the background information to the present research will be provided. It 
will also introduce the research problem, purpose, and the associated research 
questions that this research seeks to address. Finally, the structure of the research will 
be outlined. 
1.1 Background 
Managing risks in supply chains has never been as challenging as it is nowadays. The 
challenges mainly arise from increased dynamics and uncertainties combined with 
globalization. Supply chain risks have expanded, resulting in a new set of uncertain and 
unfamiliar incidents that can create chaos and disruptions, posing a number of 
significant threats to business continuity (Paulson, Kouvelis, & Li, 2011, p. 3). 
A great variety of risks exists, which can have significant effects on the short-term and 
long-term performances of supply chains. In addition to internal risks—which are 
controllable to some extent—the ever-increasing external risks continue to expose 
today’s supply chains to completely new challenges. Examples include socio-political 
disruptions, security problems, terrorism, counterfeiting, etc. (Dani, 2009, p. 55). 
The consequences of failure to manage supply chain risks have become more severe 
(Faisal, 2009, p. 42). This highlights the importance of Supply Chain Risk Management 
(SCRM). SCRM aims to identify and manage supply chain risks through a coordinated 
approach amongst supply chain members in order to reduce supply chain vulnerability 
as a whole (Jüttner, 2005, p. 124). 
Pharmaceutical supply chains are subject to a wide range of risks that may disrupt the 
continuous supply of medicines. The disruptions are not only causing disturbance and 
increased costs, but can also aggravate the patients’ health status by hindering access 
to medicines. Confronted with much greater economic, social and political instabilities, 
pharmaceutical supply chains in the developing countries are exposed to even higher 
levels of uncertainties and vulnerabilities.  
Therefore, the identification of risks and the development of mitigation strategies in the 
pharmaceutical supply chain are highly recommended (Jaberidoost, Shekoufeh, Akbar, 
& Rassoul, 2013, pp. 1,6). 
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As a result, SCRM should be an essential part of the pharmaceutical companies' 
strategies. Pharmaceutical manufacturers are the most important players in the 
pharmaceutical supply chain because their performances affect the efficiency of the 
whole supply chain. Also, pharmaceutical manufacturers are the most at stake because 
of their large investments in R&D as well as their responsibility for the quality of the 
final product. Therefore, they are in the best position to take responsibility for 
identifying and managing their supply chain risks (Mollah, Long, & Baseman, 2013, p. 
18). 
In the light of the political, economic, and social events that have recently occurred in 
Egypt, as well as the associated negative effects on the business climate (OECD, 2014, 
p. 13), it is becoming difficult to ignore the importance of identifying and managing 
risks in the supply chains of Egyptian companies. 
1.2 Research Problem 
A search of the literature was conducted through the following bibliographic databases 
and scientific search engines—ProQuest, PubMed, Science Direct, Google Scholar—
using the following keywords: supply chain, risk management, supply chain risk 
management, pharmaceutical (medicine), Egypt, manufacturers, in different 
combinations, to produce all the relevant results.  
The search revealed that only one published study addressed the issue of supply chain 
risk from the perspective of Egyptian companies in the following sectors: FMCG 
manufacturing, retailing, transport and logistic services (Elzarka, 2013). 
However, no prior empirical research was found that addresses supply chain risks in 
the Egyptian pharmaceutical sector. 
1.3 Research Purpose and Research Questions 
The purpose of this research is to: (1) identify the most important supply chain risks 
from the perspective of a pharmaceutical manufacturer in Egypt, Pharco 
Pharmaceuticals, (2) describe the current risk management strategies applied by the 
company, and (3) recommend potential strategies that can improve the management of 
risks. 
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The following set of research questions was developed to help fulfill the purpose of the 
research: 
RQ1: What are the most significant supply chain risks for Pharco? 
Objectives:  
- To identify the most important supply chain risks and understand their nature 
from the perspective of Pharco Egypt. 
- To prioritize/rank the most important supply chain risks. 
RQ2: How does Pharco manage its supply chain risks? 
Objective: 
- To identify and describe the current risk management strategies, as applied by 
Pharco, to deal with its supply chain risks.  
RQ3: How can Pharco improve its management of supply chain risks? 
Objective: 
- To make recommendations which improve the current management of supply 
chain risks, by discussing the potential strategies that can be applied to mitigate 
such risks. 
1.4 Research Outline 
The first chapter provided background information for the research, and presented the 
research problem, research purpose and research questions. 
Chapter Two presents the methodology applied for conducting this research. It 
describes the research design, case selection, and data collection instruments. It also 
discusses the research trustworthiness and limitations of the research methodology. 
Chapter Three provides a theoretical framework for the research by reviewing the 
relevant body of literature on supply chain management, supply chain risks, and supply 
chain risk management. 
Chapter Four starts by providing a brief overview of the pharmaceutical industry in 
Egypt and presents Pharco Pharmaceuticals, the case company. Finally, the risks 
identified in Pharco’s supply chain are presented. 
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Chapter Five ranks and categorizes the identified risks, followed by a discussion on the 
risk management strategies applied by Pharco. Finally, recommendations are given to 
the company to improve the management of supply chain risks. 
Chapter Six concludes with a summary of the research findings. Suggestions for further 
research are also considered at the end of the chapter. 
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2. METHODOLOGY 
This chapter presents the methodology applied for conducting this research. It 
describes the research design, case selection, and data collection instruments. Finally, 
a brief discussion on the research trustworthiness, along with the limitations arising 
from the choice of the methodology, is given. 
2.1 Research Design 
This research primarily follows a qualitative approach. The first research question aims 
to identify and rank the most important supply chain risks at Pharco, as well as to 
provide a more in-depth understanding of their nature. The second research question 
aims to describe strategies applied by Pharco to manage its supply chain risks. These 
two research questions are addressed through a descriptive case study. 
The third research question aims to make recommendations for the company, by using 
the theoretical literature based on SCM and SCRM. This part of the research is 
normative in nature. Unlike the descriptive approach, the main aim of the normative 
approach is not just to gather facts, but also to point out the respect(s) in which the 
object of study can be improved (Pentti, 2007). 
The principal unit of analysis within this research is the supply chain risk facing Pharco. 
2.2 Case Study Research Strategy 
Yin (1994, p. 13) states that A case study is an empirical inquiry that investigates a 
contemporary phenomenon within its real-life context, especially when the boundaries 
between phenomenon and context are not clearly evident. 
Benbasat, Goldstein, and Mead (1987, p. 387) identify some of the characteristics of 
case study research as follows: 
- The phenomenon is examined in a natural setting; 
- Data is collected by multiple means; 
- One or a few entities (persons, groups or organizations) are examined; 
- The complexity of the unit is studied intensively; 
- The focus is on contemporary events. 
 6 
Among the aims of this research is to develop a more in-depth description and 
understanding of the most important supply chain risks at Pharco. The case study 
approach enabled the intensive study and examination of supply chain risks facing the 
company, which generated a deep and rich understanding of the situation. 
In the case study approach, data is collected by multiple means. According to Yin 
(1994, p. 97), a major strength of case study data collection is the opportunity to utilize 
many different sources of evidence (data triangulation). This allows the development 
of converging lines of inquiry. In other words, the research finding or conclusion is 
likely to be more convincing, and accurate, if it is based on multiple sources of 
information. In this research, a combination of primary and secondary data sources was 
utilized. 
2.3 Case Selection and Data Collection 
2.3.1 Case Selection: Pharco Pharmaceuticals 
Dul and Hak (2008, p. 250) suggest that when conducting a descriptive case study, case 
selection should be governed by convenience, feasibility, and likely effectiveness. 
Pharco Pharmaceuticals is one of the largest private Egyptian pharmaceutical 
companies, operating in both local and international markets, with a complex global 
supply chain. These aspects make the company appropriate for studying the complexity 
of pharmaceutical supply chain risks. 
Moreover, the openness of Pharco’s employees and willingness to cooperate further 
encouraged the selection of the company for this research. 
2.3.2 Primary Data 
Primary data is original research data in its raw form, without any interpretation or 
analysis, and thus original in character (Kothari, 2004, p. 95). In this research, 
interviews are the most valuable prime source of information, and semi-structured 
interviews were applied for data collection. In semi-structured interviews, a researcher 
asks predetermined, but flexibly worded questions. In addition, follow-up questions can 
also be asked to more deeply probe issues of interest to interviewees (Hancock & 
Algozzine, 2006, p. 40).  
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Despite the advantages of interviews as a data collection instrument (mainly allowing 
more in-depth, rich information to be obtained and providing greater flexibility), the 
interview method also has certain weaknesses. Among the important weaknesses are 
the following (Kothari, 2004, pp. 98,99): 
1- The interview method is an expensive and comparatively more time-
consuming one; 
2- There remains the possibility of interviewer and respondent bias; and 
3- Participants may not be easily approachable. 
For this research, a total of six semi-structured interviews were conducted face-to-face 
and by telephone in the period from January 2015 to March 2015.  
The selection of interviewees directly influences the quality of information obtained 
(Hancock & Algozzine, 2006, p. 40). Accordingly, participants involved key 
experienced managers from various functional departments at Pharco, including: 
Quality Assurance Manager, Development Sector Head, Sales Manager, Import and 
Export Manager, as well as senior Returned Products Supervisor.  
In most cases, the interview time spent with each participant ranged from 45 minutes 
to one hour. All the interviews were electronically recorded, and later transcribed, for 
closer scrutiny. Transcripts were analyzed in the light of the relevant body of literature, 
and compared with data obtained from other sources. 
Having identified the important risks, a risk-ranking matrix was developed and then 
filled in by contacting the four managers to assign estimates for the impact and 
likelihood of each risk i.e. to prioritize/rank risks. In addition, follow-up telephone 
interviews were performed for further clarification. The interview protocol, which 
includes the questions asked, interviews details and risk-ranking matrix, is presented in 
Appendix 1. 
2.3.3 Secondary Data 
Secondary data are those which have already been collected by someone else and which 
may have already been passed through a particular analysis (Kothari, 2004, p. 95). 
In this research, various sources of secondary data have been used, including: 
textbooks, scientific journal articles, company documents, industry reports, internet 
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sources, newspaper articles, as well as documents and statistics obtained from the 
Egyptian Drug Authority.  
2.4 Evaluating the Quality of the Research Methodology 
Barnes (2001, p. 1078) states that any research method inevitably has both advantages 
and disadvantages, and there is unlikely to be one best way of approaching the task. In 
other words, methodologies cannot be true or false, only more or less useful, as 
Silverman (1993, p. 2) puts it. 
2.4.1 Research Trustworthiness 
In order to generate confidence in the research findings, this section will examine the 
quality of the research performed in light of the four elements of trustworthiness, as 
described by Guba (1981, pp. 79,80): 
Credibility: refers to how one can establish confidence in the “truth” of the research 
findings. In this research, triangulation—by utilizing multiple data sources and multiple 
participants—allowed the cross-checking of data and interpretations. This provided the 
researcher with complementary aspects that increased the understanding of the 
researched object (supply chain risks). 
Transferability: is the degree to which the findings of a particular research may have 
applicability in other contexts. This research addressed supply chain risks from the 
perspective of Pharco, with the aim to contribute to the knowledge of this particular 
company, rather than producing generalizable outcomes to the population. 
Accordingly, it could be argued that the transferability criterion is not satisfied for the 
research presented. 
Dependability: refers to whether the findings of the research would be consistently 
repeated, if the research were replicated with the same subject and in the same context. 
In order to increase the dependability of this research, the interview protocol, which 
includes both questions asked and interviewees, was created (See Appendix 1). 
Therefore, it is believed that asking the same questions to the same interviewees would 
produce similar results. 
Conformability: is the degree to which research findings are a function solely of 
subjects and conditions of the research, and not of the biases, motivations, interests, or 
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perspectives of the researcher. To reduce possible bias, interviews were recorded and 
transcribed, providing a permanent verbatim evidence, which can be recalled when 
needed. In addition, it is expected that data triangulation contributed toward lowering 
the potential bias induced by the researcher’s subjectivity. 
2.4.2 Limitations 
Much of the data applied in this research was derived from analyzing and interpreting 
what the interviewees were saying. Thus, it is important to acknowledge that, despite 
the use of data triangulation, interviewees’ bias as well as the researcher’s assumptions 
and interpretations could have, to some extent, affected the outcome of the research. 
In addition, since most of the data were obtained from one company, the applicability 
of research findings cannot go beyond this particular company. As a result, research 
findings are not expected to retain the same level of validity for other settings, making 
it less useful for other companies, without investigating new cases. 
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3. LITERATURE REVIEW 
This chapter presents the concepts and the theoretical framework used for this research 
by reviewing the relevant body of literature on supply chain management, supply chain 
risks, and supply chain risk management. 
3.1 Supply Chain Management (SCM) 
3.1.1 Definition and Objectives of Supply Chain Management 
Over time, dozens of definitions have been developed to describe the relatively new 
terminology of Supply Chain Management. Because this discipline is still in its early 
stages, the lack of common agreement on a uniform definition is evident.  
A number of studies has attempted to examine the existing definitions in the literature 
in order to develop a uniform definition of SCM (Bechtel & Jayaram 1997; Cooper, 
Douglas, & Janus, 1997; Mentzer, DeWitt, Keebler, Min, & et al., 2001; Stock & Boyer, 
2009). The Council of Supply Chain Management Professionals (CSCMP) and industry 
experts have created the following official definition of SCM: 
Supply chain management encompasses the planning and management of all activities 
involved in sourcing and procurement, conversion, and all logistics management 
activities. Importantly, it also includes coordination and collaboration with channel 
partners, which can be suppliers, intermediaries, third party service providers, and 
customers. In essence, supply chain management integrates supply and demand 
management within and across companies (CSCMP, 2014).  
However, this definition does not highlight the ultimate objectives of SCM. Chopra and 
Meindl (2007, pp. 5,6) state that the ultimate objectives of every supply chain are to 
satisfy customer needs and to generate profits. Similarly, Christopher (2011, p. 3) views 
the main aim of SCM as delivering superior customer value at the lowest possible cost 
to the SC as a whole. 
3.1.2 Pharmaceutical Supply Chain (PSC) 
In order to describe a typical PSC, parties that form this supply chain should first be 
identified. According to Shah (2004, p. 931) and Pedroso and Nakano (2009, p. 378), a 
typical PSC includes, but is not limited to, the following parties: manufacturers, 
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intermediaries, healthcare providers, and customers. A typical PSC is illustrated in 
Figure 3.1. 
 
Manufacturers include, among others, pharmaceutical and biotechnology 
manufacturers, medical suppliers, and medical device producers. Intermediaries 
include wholesalers, mail order distributors, and group purchasing organizations. 
Healthcare Providers include hospitals, physicians, and pharmacies. Customers 
include government, employers, and individuals. 
Manufacturers can be categorized into primary and secondary manufacturers. Primary 
manufacturers produce the active pharmaceutical ingredients (APIs) of the medications. 
Secondary manufacturers are responsible for transforming the active ingredients into 
usable drugs (e.g. tablets, capsules). After that, finished products are distributed to the 
healthcare providers through intermediaries (e.g. wholesalers, distributors). Some 
manufacturers deliver their products directly to healthcare providers and bypass 
intermediaries (Kritchanchai, 2012, pp. 103,104).  
A distinct feature of a PSC is that final consumers (patients) do not fully understand the 
medical practice; hence, they have control neither over drug choice nor over the amount 
to be consumed. As a result, healthcare providers play an important role in PSC. 
Because they write prescriptions for patients, demand for drugs is dependent on 
healthcare providers (e.g. physicians and hospitals). This feature highlights the 
importance of technical information flow for demand creation in PSC as opposed to 
other industries’ supply chains (Pedroso & Nakano, 2009, pp. 378,379). 
3.1.3 Recent Trends and Practices in Supply Chain Management  
Changes in supply chain management are triggered by a number of drivers. Waters 
(2007, pp. 53–56) and Paulson et al. (2011, pp. 63,64) identified some of the most 
important drivers as follows: 
Figure 3.1 A typical pharmaceutical supply chain 
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- Increasing recognition that logistics management is an essential function 
and needs sound management; 
- The importance of supply chain decisions and its subsequent strategic 
impact on organizations; 
- New trends in supply chains in order to adopt operations such as just-in-
time, postponement, mass customization, lean operations, etc.; 
- Increased level of globalization and international trade encouraged by 
continuous removal of trade barriers; 
- Improved communication and information technology to ease the 
implementation of new solutions, such as tracking systems; 
- Higher level of competition and access to global suppliers; 
- Trends toward supply chain integration, mergers, strategic alliances and 
partnerships; 
- Outsourcing non-core activities to third parties and focus only on core 
activities; 
- Growing concerns about environmental changes, which have affected 
attitudes toward pollution, waste, etc.; 
- The effects of changing regulatory environment and government policies on 
organizations. 
The increased complexity of supply chains makes them more vulnerable to various 
types of internal and external risks. Organizations are trying to adapt to the above 
mentioned changes by altering the way they are doing business to improve their 
operational efficiency, which in turn increases their vulnerability to risks. For example, 
globalization enables organizations to find more efficient sources of supply by 
procuring from global suppliers, but also increases the risks associated with delays, loss 
of control, and reliance on foreign suppliers. If managers do not pay sufficient attention 
to these risks, the level of risks will expand and drift upward.  
3.2 Risk in Supply Chain 
3.2.1 Risk and Uncertainty 
The term risk is still being debated among researchers. As various academic and 
professional disciplines are concerned with risk, it is difficult to find a definition that is 
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universally agreed upon. Also, the term risk is frequently used interchangeably with 
uncertainty (Ritchie & Brindley, 2009, p. 12).  
Uncertainty refers to the lack of predictability of outcomes i.e. we do not know what 
will happen in the future. This implies that the outcome(s) can be positive (provide 
opportunities) or negative (cause harm) (Kahneman and Tversky, 1982). Uncertainty 
can be categorized into internal uncertainty and external uncertainty, according to 
Kahneman and Tversky (1982), as follows: 
- Internal uncertainty: refers to the lack of knowledge and ignorance, which 
means that information is available, but the decision-maker does not know 
it. 
- External uncertainty: refers to the situation where the decision-maker has no 
control over it. 
This distinction is important in the sense that each type requires different responses 
from the decision-maker. For example, updating information can reduce internal 
uncertainty, while external uncertainty requires a more flexible approach to adapt 
unforeseen changes at the lowest possible cost. 
The term “risk” is often reserved for the negative consequence, since the inference is 
the downside (negative) impact of the uncertain outcome (Spekman & Davis, 2004, pp. 
416,417). Other authors share the same view of risk and define it as an event with the 
potential to have a significant negative impact on the organization (Agrawal, 2009, p. 
2; Hopkin, 2013, p. 1; Mollah et al., 2013, p. 8). 
Within the context of this research, the term risk will be used to indicate an event with 
potential negative consequences, whereas the term uncertainty will be used to refer to 
situations where both positive and negative consequences are considered. 
3.2.2 Supply Chain Risk 
In essence, risk in the supply chain context is viewed as disruptions of different flows 
(materials, information, and cash) that take place between supply chain parties. A key 
feature of supply chain risk is that it extends beyond the boundaries of a single 
organization (Jüttner, 2005, p. 122). 
Jüttner, Peck, and Christopher (2003, pp. 200–206) highlighted the difference between 
supply chain risk sources and risk consequences.  
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Risk sources include environmental, organizational, and supply chain-related variables, 
which have an impact on supply chain outcomes, and cannot be predicted with 
certainty. Environmental risk sources include any uncertainties stemming from supply 
chain environment interactions (e.g. socio-political actions or acts of God). 
Organizational risk sources lie within the boundaries of SC parties (e.g. production 
uncertainties or strikes). Network-related risk sources arise from suboptimal 
interactions between parties within a SC. 
Risk consequences are the focused SC outcome variables, such as cost, quality or 
demand. In other words, risk consequences are the different forms in which variance 
becomes manifest. 
3.2.3 Categorization of Supply Chain Risks 
Risks in the supply chain can be categorized into internal risks and external risks. 
Internal risks are those that are controllable—to some extent—by supply chain 
members.  
According to Mieghem (2011, pp. 19,20), potential internal risks can be categorized on 
the basis of the stages in the value chain where the negative impact may take place. 
Based on this view, identified risks can be categorized into the following seven 
categories, as shown in Figure 3.2. 
 
Figure 3.2 Internal risks within various stages of the value chain 
Source: (Mieghem, 2011, p. 19) 
Innovation risk: This refers to the potential negative impact that originates during the 
research and development phase. In the pharmaceutical industry, a new drug may not 
meet the efficacy, potency, or safety standards necessary, so as to be approved by the 
relevant governmental authority. 
Commercial risk: This refers to the associated negative impacts related to marketing 
and sales and, therefore, negatively affect revenues, such as lower than expected sales, 
which lead to reduced revenues. 
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Demand and supply risks: These refer to problems in the quantity demanded or supplied 
for a given product or service. Examples are decreased demand, which leads to 
overstocking of finished products at the retail level that must be sold at a discount, or 
problems in supplying the required inputs for production, such as a supplier’s limited 
production capacity or quality issues. 
Production and distribution risks: Production risk stems from internal processes, such 
as machine failure or capacity shortage. Distribution risk may occur as a result of 
logistics service provider failure, such as delays and damage to products during 
transportation. 
Coordination and information risks: These refer to the failure in coordinating and 
communicating information with relevant parties in the supply chain, forecasting errors, 
and information system failure. 
Service risk: This refers to problems that occur during after-sale service interactions, 
including inappropriate handling of customer inquiries and problems in product returns.  
External risks can be categorized into natural, political, regulatory, competitive and 
strategic risks. 
Natural risk refers to acts of God, such as earthquakes, fires, storms, and lightning 
strikes. 
Political and regulatory risks: Unexpected changes in laws and regulations can lead to 
negative impact on organizations. War, strikes, and revolutions may lead to political 
unrest which can also negatively affect organizations. 
Competitive and strategic risks refer to the potential negative impact of competitive 
pressure, such as changes in competitors’ strategies. 
Unlike internal risks, which are to some extent controllable by supply chain members, 
a key feature of external risks is that they are outside the control of the supply chain, as 
defined by Kahneman and Tversky (1982). In other words, managers cannot change an 
external risk, but they can deal with it by designing strategies that interact efficiently 
within a risky environment. 
Waters (2007, p. 104) also differentiates between organization-specific and industry-
wide risks. Organization-specific risks may affect an individual organization and its 
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supply chain (e.g. increased competition). On the other hand, industry-wide risks affect 
every organization within the same industry (e.g. new regulations), leaving them in the 
same boat.  
The importance of this distinction is reflected in the type of response required because 
the scope of the risk determines the appropriate response. Unlike organization-specific 
risks, a single firm cannot deal with industry-wide risks alone; there must be 
cooperation between organizations, even with competitors, to enable them to work 
together to overcome risks for their mutual interests. 
3.2.4 Risks in the Pharmaceutical Supply Chain 
Manufacturers of medicines are the main players in the pharmaceutical supply chain. 
Through complex processing, chemical materials are converted into medications. These 
companies are subject to numerous types of supply chain risks.  
Apart from the Jaberidoost et al. (2013) study, there is a general lack of research in the 
area of pharmaceutical supply chain risks. In their systematic literature review, 
Jaberidoost et al. (2013) concluded that PSCs face a total of 50 main risks classified 
into seven categories, as follows: supply risk, organization & strategy risk, financial 
risk, logistical risk, market risk, political risk, and regulatory risk. Jaberidoost et al. 
(2013, p. 1) emphasized the importance of identifying the potential risks in PSC, 
assessing their significance, and developing risk management strategies to handle them. 
3.3 Risk Management and Supply Chain 
3.3.1 Supply Chain Risk Management (SCRM) 
In supply chain literature, there are various definitions of SCRM. Jüttner (2005, p. 124) 
defines SCRM as a managerial activity that includes identification and management of 
supply chain risks, through a coordinated approach amongst SC members, to reduce 
SC vulnerability as a whole.  
Rao and Goldsby (2009, p. 106) identified the key definitions of SCRM that exist in 
the literature. They highlighted that despite the minor variations among the definitions 
of different authors, it is obvious that they share a common central theme that SCRM 
extends beyond the ideology of a single-firm risk management.  
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SCRM lies on the border between supply chain management and risk management 
(Blos, Quaddus, Wee, & Watanabe, 2009, p. 248), as depicted in Figure 3.3. 
 
Figure 3.3 SCRM lies on the border between SCM and RM  
Source: (Blos et al., 2009, p. 248) 
Generally, SCRM is similar to organizational risk management, but SCRM is much 
more complicated due to the need for cooperation and collaboration between 
organizations with different operations, aims, and views (Felea & Albastroiu, 2013, p. 
63). The main focus of SCRM is to understand and try to avoid the ripple effects that 
risks can have on SC (Norrman & Jansson, 2004, p. 435).  
Christopher (2002, pp. 38,39) suggests that the four main objectives of SCRM are to: 
- Maintain the supply and continuous availability of products; 
- Increase SC’s ability to cope with disruptions; 
- Avoid possible domino effects throughout the chain; and 
- Make the SC more resilient to disruptions. 
3.3.2 Benefits of Supply Chain Risk Management   
SCRM helps the organization and its supply chain achieve the following benefits: 
- Risk-related issues are known in advance and become a part of normal 
operations; 
- More balanced decisions are made, and operations that are financially unsound 
or too risky are avoided; 
- The performance of management can be better measured; 
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- Early identification and analysis of potential risky events enable the proper 
design, planning, evaluation, prioritization, and allocation of resources to 
develop responses that mitigate risks, as it might be too late to adapt risk when 
it is observed far down in the supply chain; 
- The absence of time constraints enables imaginative responses to be developed; 
- Quick implementation of plans and contingencies after a risky event 
materializes; 
- Better financial performance, customer service, corporate image, etc.; 
- Development of historical risks record and analytical skills of people enable the 
improvement of future responses; 
- Better communication, involvement, and understanding of relevant parties are 
ensured. 
SCRM should not be viewed as an extra burden on the organization that adds more 
work and costs, but should be viewed as a way of improving customer service, reducing 
the overall costs and enhancing performance. This recognition should encourage 
managers to adopt formal SCRM methods to deal with the increased level of risks in 
their supply chains (Waters, 2007, pp. 87,88). 
3.3.3 The Importance of the More Proactive Approaches in SCRM  
SCRM approaches can be described as being reactive or proactive. The reactive 
approach is the default option when risk materializes (Dani, 2009, p. 58). A lack of 
preparations could result in significant problems. Organizations with no risk 
management follow a reactive approach in managing their risks. Managers react after 
the occurrence of a risky event, by analyzing the problems, and then design and 
implement their response, if any. 
This approach is too slow, and may cause a considerable damage before a response 
starts to work. The result is a quick decision that has a high potential for error (Waters, 
2007, pp. 75,76). 
In contrast, a more proactive approach to managing risks is preferable. In this case, 
potential risks are identified, analyzed, and appropriate responses designed in advance, 
so as to better deal with the most important risks (Dani, 2009, p. 58). 
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3.3.4 Supply Chain Risk Management Framework 
Waters (2007, p. 90) suggests that SCRM has three core elements: identifying supply 
chain risks, analyzing them, and designing appropriate responses to the risks. These 
elements are general for all types of risk management, not only supply chain risks.  
Although these three elements are the core of SCRM, they do not capture the complete 
picture of the process. There are additional steps that take place beforehand to set the 
scene: these are the preparatory steps, as well as the monitoring and control steps, which 
take place afterward. The elements of SCRM are shown in Figure 3.4.  
In essence, the preparatory step starts with acknowledging the importance of supply 
chain risk management. Then, the organization’s attitude toward risk and its risk 
strategy should be defined, followed by setting up an organizational structure 
responsible for the risk management, involving senior management.  
Monitoring and control steps take place after the three core steps. Documentation and 
data collection are carried out throughout the supply chain to measure the effectiveness 
of the risk management process. This assist in the future identification and analysis of 
potential risks as well as allow the organization to learn and improve its risk 
management strategy (Paulson et al., 2011, pp. 3–7). 
3.3.4.1 Risk Identification  
The identification of potential risks is a key activity in supply chain risk management. 
One way to identify risks is to ask people who have intimate knowledge of the 
organization and its supply chain, including the operations and the environment within 
which they operate.  
Figure 3.4 SCRM Framework 
Source: adapted from (Waters, 2007, p. 90) 
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Another way is to ask consultants outside the organization as they can give valuable 
insights into risks; however, it is better to deal with internal people at the organization. 
Many tools are available to help identify the risks, such as: 
- Process charts and process controls 
- Interviews 
- Group meetings 
- Delphi methods 
- Brainstorming 
- Checklists 
- Five whys 
- Cause-and-effect diagrams 
- Pareto analyses 
Statistics over historical data is one of the most applied methods to identify uncertainty. 
As the higher the variance (e.g. demand, costs, prices, lead times, etc.), the higher the 
uncertainty. 
 Challenges in risk identification  
It is impossible to identify every conceivable risk to the supply chain. One reason is 
that every supply chain has its unique nature; therefore, there is no one size that fits all 
guidelines to identify all potential risks. As a result, managers should try to list the most 
significant (serious) risks and allocate their efforts toward these risks. Also, the decision 
related to the number of risks to be identified must remain a matter of management 
judgment, given the unique nature of the supply chain.  
There are however generic ways to identify and handle uncertainty. E.g., identifying 
demand uncertainty it is mostly done by a combination of historical statistics and future 
market assessment.  
Risk identification requires different sets of skills, and even people with intimate 
knowledge about the company’s operations may fail to properly identify risks. One 
example is recognizing the most obvious risks rather than the most significant risks, 
which result in producing a list of trivial risks. 
Additionally, managers may be reluctant to admit that risks exist within their 
organizations, because this implies some kind of failure or weakness. This is also a 
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result of the human bias of overconfidence. Acknowledgment that risks do exist is an 
important step (Waters, 2007, pp. 101–121). 
3.3.4.2 Risk Analysis 
The aim of risk analysis is to prioritize the identified risks, based on their significance. 
Having identified the most significant risks, managers should pay sufficient attention 
in order to control these in the step that follows. According to Waters (2007, p. 127), 
there are two approaches to risk analysis. The first approach is purely qualitative. This 
approach is useful to gain better understanding of risks, their effects and their 
consequences. Features of the identified risks are described qualitatively in terms of: 
- The nature of each risk; 
- Potential consequences/subsequent changes to operations; 
- Likelihood; 
- The scope and areas affected; 
- Responsibility for risk control; 
- Current management of risks and their efficacy; 
- Suggestions and new policies for improving the current risk management. 
According to Mieghem (2011, p. 22), a subjective risk map can be developed only on 
the basis of expert opinion, not on the basis of statistical analysis, as seen in Figure 3.5. 
Obviously, this risk map is company-specific, as the risk portfolio varies from one 
company to another.  
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Figure 3.5 Example of a company-specific risk map 
Source: (Mieghem, 2011, p. 22) 
Different risks carry different weights, depending on the company’s strategy and the 
industry within which it operates. The output of risk analysis is a ranked list of risks, 
based on the overall score of each risk, which is the combination of impact and 
probability, as seen in Figure 3.6 below. Risks with the highest scores occupy the upper 
right quadrant, whereas risks with lowest scores are located the lower left quadrant. 
 
Figure 3.6 Qualitative risk assessment assigns an overall risk level to each identified risk 
Source: (Mieghem, 2011, p. 23) 
 23 
Compared to operational risks (in which it is relatively easier to quantitatively assess 
the probability/impact values), one should consider that some risks are more difficult 
to assess, such as political and natural risks (Mieghem, 2011, p. 24). 
The second approach is based on quantitative measures, with the aim of providing 
precise and objective estimates of the likelihood of occurrence of each risk and its 
consequences (Waters, 2007, p. 128). Risks can be assessed quantitatively by 
estimating the financial impact and probability of each risk, based on historical data 
and expert knowledge. The expected impact can be quantified by multiplying the 
financial impact by the probability of occurrence (Mieghem, 2011, p. 24). 
 Risk-Ranking Matrix 
A simple and most applied method for risk analysis is the risk-ranking matrix. The risk-
ranking matrix is a table with several categories for likelihood and impact. Each row-
column pair (cell) of likelihood and impact is associated with a recommended level of 
risk, urgency, or priority. Risk levels can be distinguished by red, yellow, and green 
colors to indicate the relative importance of each risk level as high, medium, and low 
respectively (Cox Jr, 2008, pp. 497–498). 
In order to use this tool to perform a risk analysis, values of likelihood and impact are 
assigned to each identified risk, so as to give a two-dimensional view. For each 
identified risk, values of likelihood and impact are multiplied to give a risk score. Once 
scored, risks are then ranked on the basis of their relative importance. Ranges 
(weightings) for likelihood and impact can be modified to allow for different spread of 
risks (CQI, 2010, pp. 55–56). 
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In Table 3.1 and Table 3.2 below, a score of 1 for Low, 2 for Medium, and 3 for High 
is used to denote the likelihood and impact for each identified risk. Depending on the 
situation, more complex levels, with 5 or more, can be used to facilitate finer 
discrimination. 
 
 Challenges in risk analysis 
Carrying out a risk analysis can be challenging for the following reasons: 
- Lack of sufficient statistical data to derive the probability distribution of an 
event. Therefore, values are assigned on the basis of expert opinions, which are 
subject to the biases arising from individual interpretations. 
Table 3.1 Risk Ranking Score 
Source: (CQI, 2010, p. 56) 
 
Table 3.2 Basic 3x3 Risk Matrix 
Source: (CQI, 2010, p. 56) 
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- Common factors can contribute to more than one risk event and their 
occurrences can be correlated. Again, deriving such correlations is dependent 
upon subjective expert inputs. 
- The consequences of a risky event are often multifaceted i.e. the impact on 
supply chain members can materialize in various forms. Hence, accurate 
assessment of the scope and magnitude of risk event consequences require 
cross-functional, inter-organizational communication. (Paulson et al., 2011, p. 
6). 
3.3.4.3 Risk Response 
In this step, prevention plans and countermeasures are developed to lower the 
probability and/or consequences of the highly ranked risk events. The categorization of 
risks based on their nature will help devise proper mitigation strategies, leading to 
realistic expectations of what such strategies can really achieve. Mollah et al. (2013, p. 
20) states that a balance between benefits, risks, and resources must be achieved. 
According to Kahneman and Tversky (1982), external risks are beyond the supply chain 
members’ control; therefore, their proposed mitigation strategies should differ from 
those proposed to deal with internal risks. For instance, the likelihood that an 
earthquake will occur cannot be reduced; however, its consequences can be mitigated 
(e.g. by locating facilities away from risky areas or by strengthening the construction). 
In contrast, the likelihood of machine failures is largely determined by supply chain 
members. This reflects the importance of risk categorization in defining the right 
mitigation strategies (Paulson et al., 2011, pp. 5,6). 
The following are the main types of responses that can be used to manage risks within 
a supply chain: 
 Risk Acceptance 
Managers may choose to accept a given risk if it is insignificant. However, managers 
may also accept significant risks if these risks are not a major element of their planning 
problems. Trivial and small risks—with relatively low probability and insignificant 
consequences—may be ignored, especially if the cost of any remedial action is higher 
than the risk consequences. As a result, organizations knowingly accept the complete 
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consequence of the potential risk event. However, risk acceptance must be limited to 
trivial and very small risks (Waters, 2007, pp. 151,152). 
 Risk Avoidance 
According to Jüttner et al. (2003, pp. 200–207), risk avoidance refers to a situation 
where a company drops a specific product, supplier or geographical market. In other 
words, the event that triggers the risk is eliminated. In extreme cases, where no other 
option is feasible, an organization may not be able to handle the severity of the risk, 
and exits the market. 
 Risk Mitigation 
In this strategy, an organization may choose to mitigate the risk either by reducing the 
probability that a risk will occur or by reducing the consequences of the risk, because 
the risk significance is a factor of these two variables. Ideally, managers would reduce 
both the probability and the consequences of the risk (Waters, 2007, p. 157).  
According to Mollah et al. (2013, p. 20), when an organization chooses to reduce risk, 
it should try to make changes inherent in the design, so that the risks are removed 
without introducing new risks. This can be achieved by including protective measures 
or controls. One of the major aspects of mitigations strategies, is creating flexibility to 
adapt sudden/unexpected events and changes, with least costs and without disturbing 
the remaining of the system. 
 Risk Transfer 
Organizations may choose to transfer the risk to someone who is willing and able to 
handle it. The reason for risk transfer is that the cost of risk transfer outweighs the cost 
of internal management. However, when a risk is transferred, it is neither reduced nor 
eliminated. Surprisingly, the transferred risk may increase if it is transferred to an 
organization that is not able to handle it properly. The most common way of risk transfer 
is insurance (Waters, 2007, p. 157). 
These four strategies are, in principle, general, which means that they need to be 
operationalized and translated into more detailed methods to achieve the desired result 
of SCRM. To do so, all the possible responses to the risk in question should be listed; 
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then, a reasonable shortlist of responses is considered, and the best response is selected. 
Generally, the chosen response should achieve the following, as a minimum: 
- Allow supply chain flows to continue normally with minimum disruptions. 
- Allow efficient allocation of resources. 
- Be effective in dealing with risks. 
- Comply with rules, laws and regulations. 
3.3.5 Issues in Supply Chain Risk Management 
Despite the benefits of SCRM, little real progress has been made by organizations in 
this area. Waters (2007, p. 190) suggests that five levels of SCRM exist: 
1- No risk management. 
2- Risk management by individual organization working in isolation. 
3- Joint risk management with immediate partners. 
4- Integrated risk management along with more of the supply chain. 
5- Full integration along the whole chain. 
Most organizations fall within the first two levels, while Levels 4 and 5 remain a 
theoretical concept, rather than a practical proposition. Waters (2007, pp. 187–190) 
identifies the practical problems that represent barriers to more integrated SCRM as 
follows: 
- Lack of training and knowledge of this relatively new concept. 
- Unclear responsibilities. 
- No satisfactory incentives. 
- Unequal benefits to supply chain members. 
- Lack of trust and commercial sensitivity. 
- The need for considerable resources. 
- Limited communication and information sharing. 
- Differences in terminologies, working conditions and skills. 
- Complexity of decisions. 
Clearly, some problems are closely related and linked to each other. For example, the 
lack of trust and commercial sensitivity may lead to limited information sharing. This 
reason is often understandable. Spekman and Davis (2004, pp. 423–425) argue that one 
reason for lack of trust and information sharing is that partners within a supply chain 
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may take advantage of this trust and start to behave opportunistically. This view 
inevitably limits the transparency of supply chains, leaving other possible risks 
unidentified. 
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4. CASE STUDY FINDINGS 
This chapter starts by providing a brief overview of the pharmaceutical industry in 
Egypt. Then, it presents the case company Pharco Pharmaceuticals, along with a 
description of its supply chain. Finally, the risks identified in Pharco’s supply chain 
will be described. 
4.1 Overview of Egyptian Pharmaceutical Industry  
Egypt has the largest drug manufacturing base in the Middle East and North Africa 
(MENA) region, with over 120 pharmaceutical companies. In terms of volume, most 
of the demand for pharmaceuticals is met by the domestic production. 
Companies operating within the pharmaceutical industry in Egypt come under three 
categories: public sector companies, private sector Egyptian companies, and 
multinational companies. 
Pharmaceutical sales consist of generic drugs, over-the-counter (OTC) medicines, and 
patented drugs. In 2013, pharmaceutical sales totaled EGP 16.55 billion (USD 2.41 
billion); it increased to EGP 17.66 billion (USD 2.49 billion) in 2014, which represents 
+6.7% in local currency terms and +3.4% in US dollar terms (BMI, 2014, p. 8). 
The pharmaceuticals market is divided into private sales that are made to local 
pharmacies (driven by physicians’ prescriptions), and sales by public tenders to the 
Egyptian Ministry of Health (MoH) for supplying government hospitals (Watkins, 
2012, p. 52). 
Key features of the Egyptian pharmaceutical industry include (BMI, 2014, p. 73): 
- Egypt is the largest drug producer and consumer in the Middle East and Africa 
region in terms of volume. 
- Over three-quarters of the local market are controlled by the private sector. 
- One-third of the pharmaceutical market is controlled by the five largest 
companies. 
- Low labor costs and a large pool of highly trained pharmacists, engineers, and 
skilled technicians. 
- Local production of finished pharmaceuticals represents some 90% of domestic 
consumption. 
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- Imports are limited to APIs—raw materials, as well as patented and difficult-
to-produce pharmaceuticals. 
4.2 Company Presentation: Pharco Pharmaceuticals 
Pharco is a family-owned corporation that consists of a group of nine healthcare 
companies operating in the pharmaceutical field in Egypt. Pharco develops, 
manufactures, markets, distributes and exports a wide array of branded and generic 
drugs, as well as a number of licensed pharmaceutical products. 
Pharco Corporation has over 5,700 employees, and boasts over 345 million units in 
sales. The corporation is ranked number one in the Egyptian market, with a market 
share of 13.2 percent in 2011. 
Pharco Pharmaceuticals is the founder of Pharco Corporation. The company is the 
second private Egyptian shareholding pharmaceutical company. It was established in 
1984 and started production in 1987. The company formulates, produces and markets 
around 237 brands, generics, branded generics, and licensed products. Through the 
years, Pharco Pharmaceuticals has created several brands that have become market 
leaders in both local and international markets. 
Pharco Pharmaceuticals products are exported to some 57 countries around the globe. 
The company aims at providing highly effective, safe pharmaceutical products to 
patients at affordable prices. Pharco Pharmaceutical’s headquarter is located in 
Alexandria, Egypt (Pharco, 2014). 
4.3 Pharco’s Supply Chain 
The main players in the supply chain include local suppliers, API global suppliers, the 
manufacturer- Pharco-, authorized drug distributors, pharmacies, hospitals, clinics and 
patients, as shown in Figure 4.1. 
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Figure 4.1 Pharco supply chain 
This supply chain has the following characteristics: 
- Many intermediaries: Pharco sells around 237 brands, generics, branded 
generics and licensed products to over a dozen large authorized distributors as 
well as many smaller distributors.  
- Distributors have large distribution networks that cover the whole country, 
which in turn sell and distribute drugs to retail pharmacies, clinics and hospitals. 
- High level of fragmentation: members of the supply chain operate 
independently from each other, which reduces the potential for coordinated 
efforts. 
- Loss of drug information as products move downstream, because members of 
the supply chain use different coding systems, making it impossible for Pharco 
to track its products to the point of sale. Hence, the full tractability of the process 
cannot be maintained along the whole supply chain. Moreover, some 
pharmacies and warehouses still depend on paperwork to record inventory 
information. 
- Products are pushed down the supply chain, and incentives are given to sales 
force (of manufacturer and distributors) based on their annual sales target. These 
contribute to an increased stock levels and a higher probability of expiration at 
the retail level. Additionally, upstream members are reluctant to accept all 
returns of expired drugs, resulting in expired products remaining at the retail 
level. 
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4.4 Identification of Supply Chain Risks 
Based on the interviews conducted with key senior employees at Pharco, the following 
seven supply chain risks were identified: risks related to foreign currency and interest 
rate of loans, regulatory risk, supplier risk, political instability risk, strikes, counterfeit 
risk, and risk related to a lack of transparency in supply chains. 
4.4.1 Risks related to Foreign Currency and Interest Rate of Loans   
Pharco’s production inputs consist of active pharmaceutical ingredients and inactive 
ingredients (excipients). Almost all these chemical inputs are imported from global 
suppliers; therefore, their prices are tied to the exchange rate of foreign currencies and 
the cost of borrowing through letters of credit.  
According to the development sector head at Pharco, there is a significant increase in 
the prices of imported raw materials as a result of the increased exchange rate of the 
U.S. dollar against the Egyptian pound in the past two years, as illustrated in Figure 4.2. 
Therefore, the company’s total cost of production is susceptible to currency 
fluctuations. 
 
Figure 4.2 Price of 1 USD in EGP  
Source: (Bloomberg, 2015) 
The continuous deterioration in the Egyptian Pound against foreign currencies is 
affecting the overall cost of production, and subsequently reducing the profit margin of 
the company.  
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In 2013, Egypt’s credit rating has been downgraded by major credit rating agencies 
(e.g. Moody’s and Standard & Poor’s) due to the political unrest. Such movements in 
credit rating had an impact on interest rate of loans and the exchange rates of foreign 
currencies.  
Global suppliers of API no longer accept credit payments (the norm was a credit period 
of three to six months). Currently, they are demanding advance payments before 
shipping, which has resulted in an increased pressure on Pharco because of the 
difficulties in obtaining sufficient foreign currency (Head of Development Sector, 
personal communication, February 2, 2015). 
The purchasing department at Pharco divides the raw material planning order into 
scheduled purchase orders of partial shipments. The decision of the quantity purchased 
depends on a trade-off between current prices of raw materials, currency fluctuations, 
transportation and inventory costs. Timing is a crucial factor: if the current price is low, 
the purchase committee will go in for an annual contract with the supplier at a fixed 
price (Import and Export Manager, personal communication, January 26, 2015). 
4.4.2 Regulatory Risk 
The pharmaceuticals industry in Egypt is heavily regulated and this tight regulatory 
environment presents a challenge for Pharco. Strict price controls and drug registration 
and approval are the most important hurdles. 
4.4.2.1 Drug Pricing Regime 
Drug pricing regime is one of the biggest threats to Pharco. The Egyptian Ministry of 
Health is trying to keep drug prices affordable for patients. Previously, this objective 
was achieved by implementing a “cost-plus” pricing system, under which prices of 
drugs were determined by the Central Administration of Pharmaceutical Affairs 
(CAPA)(1) based on the costs of raw materials, packaging, distribution, production, 
tariffs, taxes, and fixed percentages of profit margins for manufacturers, distributors, 
and pharmacies. 
Under this controlled pricing system, retail prices of many drugs remain fixed for over 
10 years. In addition, the cost of production (including raw materials and labour costs) 
                                                 
 
(1) CAPA is an affiliate of the Egyptian Drug Authority, and it is the final drug pricing decision-maker. 
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is variable. The increasing variable costs of the cheap drugs, and the continuous 
devaluation of the Egyptian pound against foreign currencies resulted in considerable 
losses to the company and shortages in essential drugs. This is mainly due to the 
relatively low, fixed retail prices which resulted in some drugs cost more than their sale 
prices. 
Despite the introduction of a new international drug referencing system for pricing, the 
re-evaluation process for drugs that were priced under the old cost-plus system is 
challenging. Moreover, the Pricing Committee (2) evaluates drug prices every three 
years, and may announce reductions in the prices of the existing drugs, which affect the 
profitability of the company. In 2012, the prices of five products were reduced by the 
pricing committee, as shown in Table 4.1. 
Table 4.1 Price reductions for five products produced by Pharco in 2012 
Source: (CAPA, 2015) 
Product Name 
Price before 
Reduction (EGP) 
New Price 
(EGP) 
Change % 
Atelol 100mg Tabs 10 8 -20% 
Farcodarone50mg/ml Ampoule 20 18 -10% 
Eurocox 100mg Tablet 18 16 -11% 
Citro-K 1.102g/5ml Syrup 8 7 -12% 
V-Gone 50mg Tablet 3 2 -33% 
 
The main reason is that the Ministry of Health is reluctant to consider any increase in 
prices so as to maintain affordability of drugs for patients, which, in turn, affects the 
company negatively. As a result, issues of pricing policies and the associated regulatory 
environment are unresolved, which represents a risk for Pharco (Head of Development 
Sector, personal communication, February 2, 2015). 
4.4.2.2 Complex Registration and Drug Approval Processes 
The registration process of a new drug is complex and bureaucratic, which makes it 
difficult for Pharco to register new drugs. The Egyptian Drug Authority—the 
pharmaceutical regulatory body of the Egyptian MoH for drug registration and 
approval—has a complex structure, which includes various sub-organizations and 
                                                 
 
(2) The Pricing Committee is a part of the Drug Registration Department at CAPA. 
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committees responsible for drug registration and approval. Head of Development 
Sector at Pharco indicated that the registration procedures lack transparency and need 
to be streamlined. 
Samples of new proposed drugs have to be submitted by Pharco to the EDA for 
approval. The drug approval process is lengthy because samples have to be approved 
not only by the EDA, but also by other drug authorities in mature markets (e.g. U.S. 
Food and Drug Administration (FDA) (Head of Development Sector, personal 
communication, February 2, 2015). 
4.4.3 Supplier Risk 
Pharco produces around 237 finished products, and the company’s supplier base 
consists of over 800 local and global suppliers. For each product, the Bill of Material 
(BOM) includes some 20 raw materials (active pharmaceutical ingredients and inactive 
ingredients). The company is much more dependent on its global suppliers than on its 
local suppliers, because they supply the most important input for production, the active 
pharmaceutical ingredients. 
Within Pharco’s supply chain, global suppliers of active pharmaceutical ingredients add 
most of the value to the entire chain because pharmaceutical products are chosen 
primarily for their active ingredients. 
One problem of global suppliers is the delay in the shipments of active pharmaceutical 
ingredients. However, quality issues of the raw materials, such as non-conformity 
problem, pose a greater risk to the company. Samples of the imported raw materials 
must be subject to laboratory inspections by the Egyptian Ministry of Health before 
they can be released to the company. 
In case of non-conformity, strict procedures are applied to every successive shipment. 
Sampling and inspection of 100% of shipments is compulsory, until the issuance of five 
conformity decisions from the National Organization for Drug Control & Research 
(NODCAR). This process increases the time required to obtain the raw materials and 
results in delays in production and planning (See Appendix 2). 
The purchasing department at Pharco considers alternative suppliers when receiving 
quotations for sourcing active pharmaceutical ingredients. Also, the purchase 
committee at the company continuously reviews suppliers’ past experience to help 
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future purchase decisions (Import and Export Manager, personal communication, 
January 26, 2015). 
4.4.4 Strikes 
In 2011, after the January 25 revolution, employees at Pharco demanded an increase in 
their salaries, incentives and shares of annual profits. Also, members of the temporary 
staff wanted to be converted into permanent employees. The company’s management 
failed to come to an agreement, which resulted in more than 3,000 workers going on a 
strike that lasted for over two weeks before the dispute was settled. 
In 2013, employees went on a five-week partial strike, which then evolved into an open-
ended strike, after the announcement of a new decision by the Chairman of Board of 
Directors limiting their share of annual profits. The company was shut and production 
stopped for over two weeks. 
In both 2011 and 2013, strikes led to a halt in sales and production, resulting in a 
considerable influence on profitability and financial status. 
4.4.5 Political Instability 
After the January 25 revolution, demonstrations, terror attacks, and government 
opposition have elevated the political and security instability during the last four years. 
Since 2011, Egypt has witnessed six different governments with different challenges, 
ideologies and visions.  
The Egyptian Ministry of Health was led by eight ministers during the last four years, 
which resulted in the issuance of various—and sometimes conflicting—ministerial 
decrees affecting different aspects of the pharmaceutical companies, particularly those 
related to pricing. Subsequently, it has affected the company (Quality Assurance 
Manager, personal communication, February 5, 2015). 
4.4.6 Counterfeit Risk 
4.4.6.1 Types and nature of counterfeiting activities that face Pharco 
Drug counterfeiting is a serious problem that affects Pharco and its supply chain 
members. Participants highlighted the nature and types of drug counterfeiting activities 
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facing Pharco. They pointed out that counterfeiters deceive customers by passing off 
their fake products as genuine drugs.  
The most common practice of counterfeiting is to imitate packaging, label, name, logo 
and colors of the genuine drug. In addition, counterfeiters extend their activities to 
precisely imitate the shape, size and color of the finished pharmaceutical product—e.g. 
tablets, capsules, vials, etc.—in order to deliberately deceive customers into believing 
that they are buying a genuine drug. One example is shown in Figure 4.3. 
 
Figure 4.3 Samples of counterfeits along with samples of genuine products 
Source: (CAPA, 2014c) 
Counterfeiters may also re-date an already expired drug or a genuine drug very close to 
expiration to prolong the approved shelf life and sell it again. Two reasons facilitate 
such kinds of counterfeiting activity. First, the low cost of obtaining expired and drugs 
with close-to-expiry dates, and second, it is relatively easy to illegally obtain a large 
number of genuine, used (empty) packages and packaging equipment at a low cost. The 
main reason for this problem is the lax control and monitoring of the disposal process, 
as pointed out by the participants. 
Samples of seized counterfeit drugs imitating Pharco’s products were chemically 
analyzed by the NODCAR. The results showed that they contained no active 
ingredients. Instead, counterfeiters choose to use impure or inactive chemicals, artificial 
colors, ammonia, and limestone to substitute the more costly active ingredients, which 
represent a fatal threat to health. One instance of a counterfeit hair treatment drug was 
replaced by alcohol, which can cause significant harm to patients (Quality Assurance 
Manager, personal communication, January 12, 2015). 
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Statistics of the CAPA show that the total number of reported counterfeit cases followed 
an increasing trend in the last three years. Pharco experienced three incidents of 
counterfeiting in 2013, and two incidents in 2014, as shown in Table 4.2. 
Table 4.2 Statistics of counterfeit pharmaceuticals in Egypt 
Source (CAPA, 2014a) 
Year Total Cases Reported Pharco 
2010 18 0 
2011(3) - - 
2012 18 0 
2013 22 3 
2014 34 2 
Total 92 5 (5.4%) 
 
The reported cases are: imprecise copies imitating package, label, leaflet, logo, colors, 
and identifier (barcode, batch number (4), expiry/production date and registration 
number) of Pharco’s genuine drugs. The average price of Pharco’s genuine drugs that 
are copied is EGP 24. 
4.4.6.2 How do counterfeits enter Pharco’s legitimate supply chain? 
Within Pharco’s legitimate supply chain, drugs are sold to major authorized distributors 
who, in turn, sell drugs to pharmacies and hospitals. As mentioned earlier, almost all 
the raw materials used by Pharco are imported, and counterfeit raw materials cannot 
enter the legitimate supply chain. Imported materials have to be approved by NODCAR 
before they can be released to Pharco. Also, further inspections are carried out by the 
Quality Control department at Pharco to ensure the safety, quality and efficacy of the 
imported materials before they are processed.  
Counterfeit drugs can enter the legitimate supply chain in the form of finished products 
through unauthorized channels at distribution and retail levels. This occurs when the 
current measures of controlling counterfeit drugs fail to detect them. The current 
                                                 
 
(3) No data is available for 2011. 
(4) The batch number helps to track or identify the production specifications of a medication with respect 
to its strength, dosage form, and expiration date. 
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controls are checking products’ identifier and random inspections on distributors and 
pharmacies conducted by CAPA.   
Counterfeiting activities take place in clandestine places and are distributed by 
unauthorized distributors, as illustrated in Figure 4.4. These counterfeit drugs are then 
sold to pharmacies, which are attracted by discounts, bonuses and the higher profit 
margins offered by the unauthorized distributors. This practice is illegal as drugs are 
sold without invoices. Unfortunately, some pharmacists and sub-distributors engage in 
this criminal activity, which increases the vulnerability of the supply chain. 
 
Figure 4.4 Potential infiltrations of counterfeits into Pharco’s downstream supply chain 
Another way of infiltrating the legitimate supply chain occurs when products are 
returned from downstream members. Counterfeits can enter the legitimate supply chain 
if distributors fail to identify whether the returned drugs are genuine or not, as illustrated 
in Figure 4.5 (Sales Manager, personal communication, January 5, 2015). 
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4.4.7 Lack of Supply Chain Transparency 
Pharco operates in a lengthy, complex supply chain. Products are sold to over 33,000 
pharmacies, apart from hospitals and clinics (BMI, 2014, p. 83). In addition, Pharco’s 
information system is not linked to those of its supply chain members.  
Pharco’s supply chain is highly fragmented. Each member within the supply chain uses 
different, incompatible information systems, and some do not utilize any information 
system at all. At Pharco, one aspect of the lack of supply chain transparency is the 
distorted picture of the location of inventories in the network. This limits the stock 
visibility, and makes it impossible to accurately recall or trace products as they reach 
their final destinations.  
In addition, problems related to the expired products are magnified due to the loss of 
product information as it goes through the network (Sales Manager, personal 
communication, January 5, 2015). 
The identified risks are summarized in the cause-effect diagram (fishbone diagram), as 
shown in Figure 4.6. 
 
Figure 4.5 Potential infiltrations of counterfeits into Pharco’s upstream supply chain 
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Figure 4.6 Cause-effect diagram of supply chain risks at Pharco 
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5. ANALYSIS, DISCUSSION AND RECOMMENDATIONS 
This chapter begins by ranking and categorizing the identified supply chain risks. The risk 
management strategies utilized by Pharco will then be discussed in the light of the relevant 
body of literature. Finally, recommendations to improve the management of supply chain 
risks will be provided. 
5.1 Analysis and Evaluation of Supply Chain Risks 
Having identified the risks, the next step is to evaluate each risk by assigning estimates for 
the impact of each risk and for the likelihood of its occurrence. For this purpose, a risk-
ranking matrix was utilized. The identified risks were assessed by the four managers at 
Pharco, who were previously interviewed. The risk analysis was based on the scoring key 
shown below in Table 5.1 for impact and likelihood of occurrence. Then, the risks were 
ranked on the basis of the overall score of each risk, which is the multiplication of impact 
and likelihood of occurrence, as shown in Table 5.2. 
Table 5.1 Risk rating matrix scoring key 
 
Impact 
 
Likelihood of Occurrence 
 
Low (1) Medium (2) High (3) 
Insignificant (1) 1 2 3 
Minor (2) 2 4 6 
Moderate (3) 3 6 9 
Major (4) 4 8 12 
Catastrophic (5) 5 10 15 
Low Medium High 
1–3 4–6 7–15 
 
Table 5.2 Supply chain risks at Pharco, rank-wise 
Identified Potential Risks 
Risk Analysis Risk Factor 
Impact Likelihood Score 
Foreign Currency and Loans’ 
Interest Rate Risks 
4 3 12 
Regulatory Risk 3 3 9 
Political Instability Risk 3 3 9 
Counterfeit Risk 3 2 6 
Lack of SC Transparency Risk 2 3 6 
Supplier Risk 2 2 4 
Strikes 4 1 4 
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5.2 Categorizing the Identified Risks 
Waters (2007, p. 104) highlights the importance of the risk categorization because it 
reflects the appropriate type of response required. According to Kahneman & Tversky 
(1982), lack of knowledge and ignorance may cause internal risks. This means that 
particular information needed is available somewhere, but the decision-maker does not 
know it. Internal risks can be reduced or even eliminated by updating knowledge and 
information. 
On the other hand, external risks are those over which the decision-maker has no control. 
These risks cannot be eliminated, but the consequences can be reduced by, for example, 
creating flexibility in the supply chain to quickly adapt unforeseen events. 
The risks identified in Pharco supply chain are categorized into internal and external risks, 
as seen in Figure 5.1. 
Risks related to foreign currency and the interest rate of loans, political instability and 
regulatory risks are the highest ranked risks at Pharco. All these highly ranked risks come 
within the category of external risks, which means that Pharco’s supply chain cannot 
eliminate them. The next section discusses how Pharco deals with the identified risks. 
5.3 Managing External Risks at Pharco Supply Chain 
5.3.1 Risks related to Foreign Currency and Interest Rate of Loans 
The purchasing department at Pharco follows a flexible approach to mitigate these risks, 
by utilizing two buying strategies to reduce the consequences of price changes in the active 
Figure 5.1 Categorization of supply chain risks at Pharco 
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pharmaceutical ingredients as a result of foreign currency fluctuations and changes in 
interest rate of loans. 
The first is a hand-to-mouth buying strategy, which enables Pharco to reduce the risk of 
price change -through the purchase of many smaller shipments- in case of high price 
uncertainty. In this strategy, decisions are updated after the purchase of each small 
shipment. Then, the next decision is made when more information becomes available for 
the company, and when market conditions make it feasible to do so. 
Moreover, this strategy helps Pharco economize on the required foreign currency to 
purchase the active pharmaceutical ingredients in case of difficulties in obtaining enough 
foreign cash. As mentioned in Section 4.4.1, API suppliers currently demand immediate 
payments, which result in pressure on the required foreign cash flow; thus, hand-to-mouth 
strategy helps the company alleviate this problem. 
The second strategy is forward buying, which enables Pharco to take advantage of the 
situation and save money by going in for longer contracts when prices are relatively low 
and, hence, reduce the risk of exchange rates moving unfavorably. 
According to Handfield (2008, p. 3), in today’s turbulent business environment, up or 
down price changes in raw materials (e.g. due to foreign exchange rate fluctuations) are 
rapid and can have significant effects on business. Defining the most appropriate purchase 
strategy is critical for organizations who face this challenge. 
Handfield (2008, p. 3) suggests that if the prices are expected to go up, organizations may 
utilize one of the common strategies (e.g. forward buying and hedging) to stockpile raw 
materials in order to reduce cost (buy in larger-than-normal quantities and store these for 
future use). 
Contrariwise, when prices are expected to fall down, organizations may choose to utilize 
a hand-to-mouth buying strategy. In this strategy, frequent purchases of smaller quantities 
help organizations save money and reduce risk. Organizations may also adopt a hand-to-
mouth strategy to secure its foreign cash flow in case of cash flow constraints (Sollish & 
Semanik, 2005, p. 309). 
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5.3.2 Regulatory Risk 
The drug registration process in the Egyptian Ministry of Health is convoluted and overly 
bureaucratic. Until recently, it could take up to three to five years to register a new drug 
in Egypt. Moreover, the pharmaceutical sector in Egypt is one of the few sectors that 
operate under strict price controls. The risk of possible downward pricing spiral is evident 
as CAPA -the final drug pricing decision-maker- continues to announce decreases in the 
price of many drugs (including Pharco’s products), which directly affect the profitability 
of the pharmaceutical companies (BMI, 2014, pp. 66–69). 
Pharco accepts the risk of downward pricing of its drugs for two reasons. First, the 
company continues to produce drugs which were down priced as long as their losses are 
offset by those drugs which make higher profits. Second, Pharco’s social responsibility 
towards patients contributes to the acceptance of this risk, even though it might not be 
economically feasible for some drugs, as indicated by the interviewees. 
A number of studies have indicated that regulatory risk (e.g. problems caused by new or 
existing regulations) is one of the major risks affecting the pharmaceutical supply chain 
(Enyinda, Mba, Manu, & Adase, 2009, p. 538; Kamath, Kamath, Azaruddin, & 
Subrahmanyam, 2012, p. 284). In 2009, a global survey of executives in the pharmaceutical 
industry was conducted, and results showed that pharmaceutical companies perceive the 
regulatory risk to be one of the biggest threats to their business (KPMG, 2009, p. 4). 
5.3.3 Political Instability Risk 
Instabilities of political, security and economic situations are critical to supply chains 
(Handfield, 2008, p. 15). The current and potential political instability in Egypt expose 
supply chains to an increasing political risk (Banham, 2014, p. 24). According to BMI 
(2014, p. 9), the political upheaval in Egypt is affecting businesses and increasing risks in 
the short and long terms. 
A country risk report produced by AMB (2014) (See Appendix 3) indicates that Egypt’s 
political risk is considered a very high risk, compared to the world average, as seen from 
the radar chart in Figure 5.2. In this report, political risk is assessed on the basis of the 
scores for nine different aspects scored on a scale of one to five, with one being the least 
amount of risk and five being the highest amount of risk. 
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Figure 5.2 Egypt’s political risk summary 
Source: (AMB, 2014, p. 3) 
One aspect of the political risk is government stability, which measures the extent to which 
a government is stable (AMB, 2014, p. 4). This aspect has the highest risk score of 4 out 
of 5, compared to the world average of a slightly more than 2.5. This score indicates a high 
level of government instability. 
Since 2011, the Egyptian Ministry of Health has been led by eight ministers with various 
ideologies and visions. This has resulted in various amendments related to the pricing 
regime. More importantly, these changes in the pricing system are negatively affecting 
local drug manufacturers, such as Pharco (BMI, 2014, p. 71). 
Interestingly, initial interpretations of the highly ranked risks at Pharco suggest that there 
may be links between them. In other words, these risks appear to be interrelated and may 
have effects on each other, as seen in Figure 5.3. A possible explanation for this is given 
in the section that follows. 
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Figure 5.3 Potential interactions between supply chain risks at Pharco 
Since Egypt’s economic situation is intrinsically linked to its political one, the political 
unrest will have an effect on the country’s economic situation, and therefore, may cause 
fluctuations in the local currency and the country’s credit rating. As a result, the prices of 
imported active pharmaceutical ingredients would be directly affected. 
Regulatory risk—through strict price controls—interacts with the currency fluctuation risk 
and acts as an amplifier for it. When the prices of active pharmaceutical ingredients 
increase due to currency fluctuations, Pharco takes the whole risk, and faces higher costs 
because of the fixed retail prices and the increased variable cost.  
In other words, the cost increase due to changes in the price of active pharmaceutical 
ingredients cannot be passed to, or shared with, other members in Pharco’s supply chain. 
As a result, the company bears the whole risk of the cost increase. The reason is that profit 
margins of both distributors and pharmacies are determined by law, as fixed percentages 
(5) of the retail price. Moreover, retail prices are fixed, and cannot be changed without 
negotiations with the relevant governmental body, which are complex and bureaucratic. 
Faisal (2009, pp. 42,43) highlighted the importance of understanding interactions between 
risks. The reason is that examining risk factors in isolation may lead an organization to 
either overestimate or underestimate its risk exposure. Also, Chopra and Sodhi (2004, p. 
53) state that by understanding the interconnectedness of supply chain risks, managers will 
                                                 
 
(5) For detailed information about pricing, the reader is referred to Pricing Ministerial Decree No. 
499/2012, http://www.eda.mohealth.gov.eg/Articles.aspx?id=26 (Last accessed April 25, 2015) 
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be able to ensure balanced and effective risk-reduction strategies that are tailor-made for 
their companies. 
5.3.4 Counterfeit Risk 
The continued presence of counterfeit medicines is considered to be one of the significant 
challenges that confront pharmaceutical companies operating in the Egyptian market 
(BMI, 2014, p. 68).  
Based on CAPA statistics related to counterfeits and the interviews conducted at Pharco, 
the counterfeiting activities facing Pharco are completely fraudulent products which 
contain entirely different contents and with packaging that look somewhat similar to the 
genuine drugs. 
These imprecise copies of Pharco’s genuine medicine can be detected when entering the 
legitimate supply chain by checking the product identifier (barcode, batch number, 
expiry/production date and registration number). However, the company does not apply 
specific controls dedicated toward mitigating the risk of counterfeit medicines, as all the 
counterfeit cases were detected and seized through random inspections conducted by 
CAPA. 
Surprisingly, Pharco has no clearly defined strategy to manage counterfeit, regulatory, and 
political risks. This implies that the company follows a risk acceptance strategy with 
respect to these three risks. This contradicts Waters' (2007, pp. 151,152) suggestion that 
the risk acceptance strategy must be limited to only trivial and very small risks. A possible 
explanation might be that these risks are perceived to be outside the control of decision-
makers, and so are neglected. 
5.4 Managing Internal Risks at Pharco Supply Chain 
5.4.1 Lack of Supply Chain Transparency 
The lack of supply chain transparency is evident at Pharco. The company’s lengthy and 
complex supply chain limits the accessibility to high-quality information. The absence of 
a uniform information system and the use of paperwork to record product information at 
the retail level are the main reasons for such a lack of supply chain transparency. No 
strategy was applied to mitigate this risk at Pharco’s supply chain. 
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Lack of supply chain transparency and hesitancy in sharing accurate and timely 
information with supply chain partners contribute to the supply chain’s inability to perform 
as intended (Spekman & Davis, 2004, p. 420). 
Moreover, in most cases, organizations are not able to recognize the actual sources of risks 
without transparency because it is assumed that the majority of risks is invisible to them 
(Kersten, Boger, Hohrath, & Spath, 2006, p. 11). 
5.4.2 Supplier Risk 
Within Pharco’s supply chain, global suppliers of active pharmaceutical ingredients add 
most of the value to the entire chain, because drugs are chosen primarily for their active 
ingredients. APIs are the most important input for production at Pharco, because they are 
the main component of the drugs, and they represent a large share of the cost price. 
Pharco utilizes two strategies to reduce the risk that arises from its APIs global suppliers. 
The first strategy is a multiple sourcing strategy, when receiving quotations for sourcing 
active pharmaceutical ingredients. This enables the company to secure the supply of inputs 
in cases of delay or non-conformity. In other words, Pharco utilizes this strategy to reduce 
the consequences of supplier risk through the increased flexibility, by having alternative 
sources. 
The second strategy is vendor (supplier) rating. Pharco continuously reviews its API 
suppliers’ past experiences to help in future purchase decisions. This is important for 
Pharco to identify the critical factors in suppliers’ performance as well as their relative 
importance and, subsequently, avoid potential risks arising from suppliers. Thus, this 
strategy reduces the likelihood of supplier risk. 
For most organizations, suppliers represent a major source of risk (Waters, 2007, p. 163). 
According to Silbermayr and Minner (2014, p. 37) and Tang (2006, p. 35), sourcing from 
multiple suppliers is the most common approach to deal with and reduce supplier risk. 
Costantino and Pellegrino (2010, pp. 27,28) also summarized the advantages of adopting 
a multiple sourcing strategy in a risky environment. Typical advantages include: securing 
alternative sources in case of delivery problems, reduced probability of bottlenecks due to 
insufficient production capacity to meet peak demand, and more flexibility to deal with 
unexpected events that could endanger supplier’s capacity. 
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According to Waters (2007, p. 163), one way to reduce supplier risk is to utilize vendor 
rating. Vendor (supplier) rating is a general term for seeing how well a supplier matches 
the requirements of its customer. Vendor rating helps organizations evaluate potential 
suppliers and choose the one that gives the least level of risk. 
5.5 Recommendations for Pharco 
5.5.1 Potential Approaches to Improve the Management of Industry-wide Risks 
Like Pharco, other local drug manufacturers in Egypt are operating within the same 
regulatory environment, which is mainly characterized by a strict pricing regime. Also, 
they import around 85 percent of their main raw materials—APIs—because of their limited 
capacity to produce these (BMI, 2014, pp. 29,33). Therefore, some of the risks identified 
at Pharco appear to be industry-wide risks—in particular, those related to the regulatory 
environment and changes in the prices of imported APIs. Industry-wide risks affect 
organizations within the same industry, leaving them in the same boat (though the degree 
of their exposure to risks may vary). As a result, there should be cooperation between 
organizations, even between competitors, enabling them to work together to overcome 
risks in their mutual interests. Accordingly, with respect to industry-wide risks, 
recommendations for Pharco will be partly based on this cooperative approach. 
5.5.1.1 Consortium Purchasing 
Regarding the risk of price increases in the imported APIs, consortium purchasing could 
be advantageous to Pharco in mitigating this risk. Consortium purchasing(6) can be defined 
as the cooperation between two or more organizations in a purchasing group in one or 
more steps of the purchasing process in order to achieve various benefits (Schotanus & 
Telgen, 2007, p. 53; Tella & Virolainen, 2005, p. 162). 
Nollet and Beaulieu (2003, p. 9) state that consortium purchasing should expand 
tremendously in circumstances where the marketplace forces organizations, which are 
normally competitors, to put together some of their purchasing activities. 
                                                 
 
(6) In the literature, various terms are used to refer to this concept, such as: horizontal cooperative purchasing, 
group purchasing, pooled purchasing, alliance purchasing, collaborative purchasing, collective purchasing, 
joint purchasing, shared purchasing, bundled purchasing, etc.  
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In addition to other advantages, typical advantages of consortium purchasing include 
reduction in supply risks, lower purchasing prices, lower transaction costs, and reduction 
in logistics costs. Chae and Heidhues (2004, pp. 1,2) also explained how an organization 
can gain advantages by engaging in consortium purchasing. They pointed out that members 
of a consortium purchasing would be risking only part of their business. Stated differently, 
consortium purchasing facilitates risk sharing between its members. 
The implementation of this strategy would entail a high level of cooperation and 
collaboration between Pharco and its potential partners (other local manufacturers) to 
better understand factors that play important roles in the success or failure of consortium 
purchasing. In addition, careful assessment of the associated costs, risks and benefits—as 
well as the choice of a suitable organizational form—is crucial if Pharco is willing to 
consider this strategy. 
5.5.1.2 Joint Pressure Group 
According to Waters (2007, p. 157), instead of accepting risks that are outside the supply 
chain members’ control—such as regulatory risk—an organization, usually through joint 
pressure group, may try to oppose a change by resisting it and try to prevent it from 
happening. Pressure groups seeks to influence people who have power to make decisions, 
e.g. policy makers or legislators. This can be achieved by campaigns or lobbying, as 
managers may utilize these to influence political or regulatory climate affecting their 
organizations. 
This could be a possible strategy for Pharco and other local manufacturers by working 
together to reduce the regulatory risk posed by the strict pricing regime and forced 
reductions of drug prices. 
Currently, the Egyptian Ministry of Health is proposing further amendments to the current 
pricing regime with the main goal of “keeping prices affordable for patients,” and has 
subsequently increased uncertainties for drug manufacturers with respect to the potential 
new pricing regime (Faten, 2015). 
It is important for Pharco to carefully assess the chance of success of engaging in such 
oppositions (if a pressure group decided to do so), as it depends on many factors, including 
their relative power and other socio-economic aspects. If the probability of success is low, 
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then Pharco should better save its time and resources by spending them in adjustment to 
the new situation. 
5.5.2 Taking a More Proactive Approach toward Managing Risks 
Christopher (2003, p. 18) states that socio-political disruptions—such as regulatory 
changes, protests or strikes—rarely occur without warning. He also suggests that routine 
scanning of the business environment should enable the identification of threats of this 
kind.  
Lee (2004, p. 6) highlights the importance of developing a team that knows how to invoke 
backup plans so as to tackle crises with contingency plans. A contingency plan serves as a 
blueprint for a timely and complete response to a specific risk(s). Organizations which are 
linked via complex supply chain networks should develop contingency plans in order to 
minimize the potential negative impacts of disruption on their supply chain performance 
levels (Skipper, Hanna, & Cegielski, 2009, pp. 40,42). 
According to ManMohan S. Sodhi and Tang (2009, p. 36), the advance development of 
contingency plans for different types of disruptions would certainly reduce the 
consequences of risks by identifying and implementing actions/strategies beforehand.  
Craighead, Blackhurst, Rungtusanatham, and Handfield (2007, pp. 146,147) suggest that 
one possible capability for mitigating supply chain risks is the Warning Capability. It refers 
to interactions and coordination of supply chain resources to detect pending or realized 
risk(s), and subsequently, disseminate relevant information to supply chain members. The 
quicker a supply chain risk is detected, and the quicker pertinent information about it is 
disseminated, the more time a supply chain would have to prepare itself for dealing with 
the negative effects of the risk, and the less severe it would likely be. 
Socio-political disruptions have become frequent during the past four years in Egypt, 
which increases the potential negative impact on companies. A recent study by Elzarka 
(2013) concluded that Egyptian companies from various business sectors have a low 
degree of preparedness to deal with supply chain risks. This was demonstrated by their 
reactive actions to recover from the recent socio-political disruptions, since they did not 
have previous plans to mitigate risks. The study also recommends that Egyptian companies 
should follow a more proactive approach in managing their supply chain risks.   
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Therefore, Pharco—in cooperation with its key supply chain members—should draw up 
contingency plans and develop a crisis management team to deal with such events. This 
team should continuously identify, measure, and evaluate disturbances within the 
operating environment. Gathering and analyzing the relevant data, for example, about the 
socio-political situation in Egypt will facilitate the discovery of relationship and patterns 
that would help identify potential disruptions in advance.  
Regarding the political disruptions, it is also recommended that Pharco should consult 
experts from the field of political science, and more preferably, involve them in the process 
of identifying and analyzing such kind of events. Elzarka (2013, p. 489) suggests that 
experts from political science field would provide valuable insights for Egyptian 
companies into the local and international political situation, which are not possessed by 
business experts. 
On the basis of that, it would be possible be project probable future scenarios and develop 
proper plans for different situations, enabling the company and its supply chain members 
to be well prepared to deal with the potential risks. 
Doing so will only be possible if Pharco has some degree of flexibility in its processes to 
deal with different threats. Also, having well trained managers and employees with the 
appropriate set of tools and techniques, which enable them to develop the right contingency 
plans, is crucial for this strategy. In addition, roles and responsibilities of supply chain 
members must be agreed upon, implying higher levels of coordination and collaboration. 
Contingency plans are not free, and all their associated costs need to be justified by the 
decision-maker. 
5.5.3 The Need for Improved Supply Chain Transparency 
Internal risks arise because relevant information about the supply chain cannot be obtained. 
While every single member has better information about itself, risks arise due to a lack of 
relevant information about other members in the supply chain. In order to reduce risks, 
supply chain members should obtain more information from other key members (Yu, 
Hong, & Cheng, 2001, p. 115). 
Supply chain transparency means that important information is captured, analyzed and 
readily available to help supply chain partners in making decisions, mitigating risk, and 
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improving processes. Consequently, supply chain transparency brings benefits to risk 
management (Caridi, Moretto, Perego, & Tumino, 2014, pp. 1–3). 
Lack of transparency weakens supply chain partners, by letting them make decisions 
without having detailed knowledge of what is happening in the rest of the supply chain, 
and subsequently it represents a risk for the supply chain (Jain & Benyoucef, 2008, p. 471). 
As indicated by the interviewees, Pharco currently has a rather low level of transparency 
with respect to its supply chain. The achievement of a high level of supply chain 
transparency at Pharco depends on the close collaboration with its key partners, upstream 
and downstream. This necessitates, as a prerequisite, greater communication and 
information sharing between Pharco’s key supply chain partners. 
One aspect of supply chain transparency is to have a clear picture of the locations of 
inventories in the network. This will enable a timely and effective response when a 
disruption does occur, because information provides higher levels of visibility and greater 
flexibility in planning. As a result, a company would know which materials to reroute, 
which production resources to redeploy, how to adjust capacities, and how to revise 
production plans (Chad, Autry & Sanders, 2011, p. 316). 
On the upstream side, Pharco can reduce supplier risk through improved transparency by 
increasing the level of communication and information sharing with its key global 
suppliers to enable signaling alerts of potential disruptions (e.g. delays in the raw material 
flow). 
In case of deviations in the supplies of raw materials (particularly of active pharmaceutical 
ingredients), Pharco has to be informed by its suppliers or other relevant parties (e.g. 3PL). 
Depending on the type of deviation, Pharco should collaboratively make responsive 
corrective actions through a pre-defined contingency plan. One example that shows how 
information sharing can help mitigate risks form suppliers is given below. 
A major pharmaceutical company has deployed an information system for transportation. 
This system tracks the departure and arrival times of shipments through high-risk 
distribution channels. In case the average “planned” time is exceeded by a certain 
parameter, a “trigger” is sent to the company. Such a trigger alerts the management to take 
action to mitigate the impact of the disruption as quickly as possible (Handfield, 
Blackhurst, Elkins, & Craighead, 2008, p. 43). 
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On the downstream side, implementing a track-and-trace system will allow Pharco to know 
where the products are at a timely manner, and follow them forward through the 
distribution chain. Other supply chain members (e.g. distributors and pharmacies) will be 
able to trace and verify past locations of products. This improved transparency will help 
reduce the risk of counterfeit drugs. 
Track-and-trace technologies are considered an important component for reducing the risk 
of counterfeits (OECD, 2008, p. 367). Track-and-trace systems use serialization to assign 
a unique identifier to products. As a result, unauthorized products cannot be accounted for 
throughout the supply chain, and will be treated and removed from the market. 
A number of technologies can be used to store the unique identifier of the product, such as 
barcodes, electronic product code, Radio Frequency Identification (RFID), or long-digit 
serial number (Gostin & Buckley, 2013, p. 183).  
Given the numerous technologies, each with different characteristics and advantages, the 
adoption of any given technology is complex. This decision involves issues, amongst 
others, of cost, compatibility, feasibility, and reliability (OECD, 2008, p. 367). Gostin and 
Buckley (2013, pp. 183–189) provide a detailed examination of different track-and-trace 
systems used in the pharmaceutical industry. 
The potential benefits of improved transparency are illustrated in Figure 5.4. 
Figure 5.4 Potential benefits of improved transparency in Pharco’s supply chain 
 
Figure 5.4 Potential benefits of improved transparency in Pharco’s supply chain 
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5.5.4 Considerations for Adopting the Recommended Approaches 
Obviously, the given recommendations are general approaches that could be beneficial to 
the company in managing risks. However, with so many strategies available to 
operationalize them, Pharco must determine how to adapt these general approaches to its 
particular circumstances. Generally, any decision to implement a particular strategy should 
be made in the light of the following considerations: 
 Costs versus benefits 
Having defined the potential strategies (alternatives) to be considered, Pharco must 
conduct a cost-benefit analysis to help appraise the value of each strategy in improving the 
management of supply chain risks. The basic rationale of cost-benefit analysis lies in the 
idea that things are worth doing if the benefits that result from doing them outweigh their 
costs (Sen, 2000, p. 934). In addition, each of the choice of an alternative must be 
considered in relation to other potential alternatives, because one alternative might exclude 
others. 
Essentially, each strategy must be evaluated on the basis of: (1) the positive effects 
(benefits) on a particular risk(s), and (2) the negative effects (expected total costs). For 
example, if Pharco considers a specific track-and-trace system to be implemented—to 
reduce the risk of counterfeit and improve transparency—the benefits of this system must 
outweigh its costs in order to justify the decision-maker’s selection of this particular 
system. 
Conceptually, the given recommendations would enhance the management of supply chain 
risks at Pharco, which would eventually lead to a better competitive position of the 
company and its supply chain, especially if competitors are exposed to the same set of 
supply chain risks. However, it is difficult to quantify the value of improved 
competitiveness, so the company needs to carefully assess the outcomes of each potential 
strategy. 
In addition, all the recommended approaches require some resources in terms of 
investment and people because preparing for risks has always some early extra costs and 
potentially uncertain outcomes. Therefore, if a given risk never materializes, it becomes 
very difficult to justify the time and cost spent on developing and implementing the 
associated strategy (Zsidisin, Panelli, & Upton, 2000, p. 196). Thus, some approaches—
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such as being more proactive by developing contingency plans—can be viewed as 
“insurance premiums.” Because it is more difficult to evaluate their returns, if risks never 
materialize, especially when reliable data for probability that a risk would occur and its 
impact are lacking (ManMohan S Sodhi & Tang, 2012, p. 106). 
It is worth noting that it is not always possible to obtain good estimates for the probability 
of occurrence of a given risk, and accurately measure its potential impact. As a result, it 
becomes difficult to evaluate the total costs of such events occurring against the benefits 
realized from having strategies in place to deal with them (Dani, 2009, p. 58). This is 
especially true with respect to risks, such as political instability and regulatory changes.  
 Strategic fit 
The recommended approaches will not be very effective if they do not fit the company’s 
overall business strategy. Strategic fit means that both supply chain strategies and 
company’s business strategy have aligned (consistent) goals (Chopra & Meindl, 2007, p. 
24). Thus, any potential strategy to manage supply chain risks must fit Pharco’s business 
strategy to form a coordinated overall strategy. To clarify this, let us consider the simplified 
example in the section that follows. 
Currently, Pharco maintains a large number of suppliers of APIs within its supply base to 
secure its supplies of APIs. Consider, for example, that the company decides to invest in a 
new joint information system with its global suppliers to improve transparency and 
mitigate the impact of disruptions in the supply of APIs. This requires Pharco to rationalize 
its supply base (i.e. reduce the number of suppliers of a particular type of APIs), since it is 
costly to develop a higher level of collaboration (strategic relationship) with many 
suppliers; otherwise, such strategy would seem to be an inconsistent strategy. 
This example indicates the importance of a strategic fit when assessing potential strategies 
to manage supply chain risks. Lack of strategic fit results in conflicts arising within the 
firm or across the supply chain, leading to suboptimal supply chain performance. The main 
reason is that different functions within the company—and different members within the 
supply chain—may be targeting different, inconsistent goals (Chopra & Meindl, 2007, p. 
25). 
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6. CONCLUSION AND FURTHER RESEARCH 
This chapter concludes with answers to the research questions by summarizing the 
research findings. Thereafter, it provides suggestions for potential further research. 
6.1 Conclusion 
The recent economic, social, and political events that have occurred in Egypt have exposed 
the pharmaceutical supply chain to higher levels of uncertainties and vulnerabilities. These 
make it extremely difficult to ignore the importance of supply chain risk management. 
Owing to the importance of the manufacturer’s performance in the pharmaceutical supply 
chain, this research sought to answer the following questions from the perspective of an 
Egyptian pharmaceutical manufacturer, Pharco:  
- Research Question 1: What are the most significant supply chain risks to Pharco? 
The research has identified seven types of risks, which were categorized into external and 
internal supply chain risks. Then, the identified risks were ranked using a risk-ranking 
matrix. 
Risks related to foreign currency and interest rate of loans, regulatory risk, and political 
instability risk were ranked high risks. On the other hand, counterfeit risk, lack of SC 
transparency risk, supplier risk and strikes were ranked medium risks. 
This finding indicates that external risks were perceived to be more significant than internal 
risks. The research has also provided an explanation of possible interactions between the 
identified risks, which enhances Pharco’s understanding of the interconnectedness of its 
supply chain risks. The understanding of risk interactions is of key importance because it 
offers valuable insights for Pharco to devise tailor-made, balanced and effective risk-
reduction strategies. 
- Research Question 2: How does Pharco manage its supply chain risks? 
The research has described the strategies applied by the company to deal with its supply 
chain risks. Hand-to-mouth and forward buying strategies are utilized to reduce the risk of 
currency fluctuations and interest rate of loans. Multiple sourcing and vendor rating are 
also used to deal with supplier-related risks. 
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However, these strategies do not reflect the importance of a joint risk management 
approach, since they are only used by the focal company in isolation of other supply chain 
members. An implication of this is the poor level of awareness with respect to the 
importance of SCRM at Pharco. 
Another important finding to emerge from this research is that despite the significance of 
regulatory and political instability risks, no clear strategy was utilized by Pharco to deal 
with them. 
These findings seem to be consistent with those of Elzarka (2013), who concluded that 
SCRM awareness is still poor among a sample of Egyptian companies from various 
business sectors. She also reported that the companies that were studied were not prepared 
to deal with socio-political disruptions, as evidenced by the lack of dedicated risk 
management strategies. 
- Research Question 3: How can Pharco improve its management of supply chain 
risks? 
Based on the findings of the previous two research questions, recommendations were made 
to improve the management of supply chain risks at Pharco. The recommended approaches 
were mainly centered on the concept of cooperation, not only between supply chain 
members, but also between potential Egyptian pharmaceutical manufacturers, enabling 
them to work together to overcome risks in their mutual interests. 
Costs-versus-benefits and strategic fit were highlighted as key considerations for 
operationalizing any of the recommended approaches. The research findings are briefly 
summarized in Table 6.1. 
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Table 6.1 Summary of research findings 
Identified SC Risks 
Ranking/ 
Evaluation 
Current 
Strategies Utilized 
by Pharco 
Recommended Approach 
to Improve the 
Management of SC Risks 
External 
SC Risks 
Risk related to 
Foreign Currency 
and Loans’ 
Interest Rate  
High (12) 
-Hand-to-mouth 
buying 
-Forward buying 
-Utilize Consortium 
Purchasing 
Regulatory Risk High (9) - 
-Create Power through 
Joint Pressure Group 
Political 
Instability Risk 
High (9) - 
-Develop Contingency Plans 
and Crisis Management 
Team 
-Consult Experts from 
Political Science Field for 
Risk Analysis 
Counterfeit Risk Medium (6) - 
Invest in Track-and-Trace 
System 
Internal 
SC Risks 
Lack of SC 
Transparency 
Risk 
Medium (6) - 
Improve SC Transparency 
through Greater 
Communication and 
Information Sharing  
-New information 
technology system, that 
enable real-time 
information for each part in 
the SC 
Supplier Risk Medium (4) 
- Multiple Sourcing 
- Vendor Rating 
Develop Higher levels of 
Cooperation and 
Information Sharing with 
Key Suppliers of APIs  
Strikes Medium (4) - 
Develop Contingency Plans 
and Crises Management 
Team 
 
6.2 Suggestions for Further Research 
It is recommended that further research be undertaken in the following areas: 
- Targeting a large sample of companies could usefully identify potential variations 
among the Egyptian pharmaceutical companies in terms of their exposure to and 
preparedness to deal with supply chain risks. Also, a typology of risks in the 
pharmaceutical supply chain can be developed, which further enhances the 
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understanding of the prevailing risks and enable the development of appropriate 
risk mitigation strategies for supply chains. 
- It would be also interesting to compare experiences of local pharmaceutical 
manufacturers with those of multinationals operating in Egypt. A close 
examination of risk management strategies is desirable to extend the knowledge of 
the Egyptian companies, enabling them to learn and improve their management 
approaches.
 62 
REFERENCES 
Agrawal, R. C. (2009). Risk Management. Jaipur, IND: ABD Publishers. 
AMB. (2014). Egypt Country Risk Report AMB Country Risk Report. 
http://www3.ambest.com/ratings/cr/reports/Egypt.pdf. 
Banham, R. (2014). Political risk and the supply chain. Risk Management, 61(5), 22–
26.  
Barnes, D. (2001). Research methods for the empirical investigation of the process of 
formation of operations strategy. International Journal of Operations & 
Production Management, 21(8), 1076–1095.  
Bechtel, C., & Jayaram , J. (1997). Supply Chain Management: A Strategic 
Perspective. The International Journal of Logistics Management, 8(1), 15–34. 
doi: http://dx.doi.org/10.1108/09574099710805565 
Benbasat, I., Goldstein, D. K., & Mead, M. (1987). The case research strategy in 
studies of information systems. MIS Q., 11(3), 369–386. doi: 
http://dx.doi.org/10.2307/248684 
Bloomberg. (2015). US dollar-Egyptian pound exchange rate.  Retrieved April 25, 
2015, from http://www.bloomberg.com/quote/USDEGP:CUR/chart 
Blos, M. F., Quaddus, M., Wee, H. M., & Watanabe, K. (2009). Supply chain risk 
management (SCRM): a case study on the automotive and electronic 
industries in Brazil. Supply Chain Management, 14(4), 247–252. doi: 
http://dx.doi.org/10.1108/13598540910970072 
BMI. (2014). Egypt Pharmaceuticals and Healthcare Report Q1, Business Monitor 
International (pp. 1–100). London. 
CAPA. (2014a). Inspection Memorandum 2010–2014. Retrieved March 10, 2015, 
from http://www.eda.mohp.gov.eg/Articles.aspx?id=34 
CAPA. (2014c). Inspection Memorandum for 2014, Part 2. Retrieved March 1, 2015, 
from 
http://www.eda.mohp.gov.eg/Files/340_Inspection%20Memorandum%20for
%202014_2.pdf 
CAPA. (2015). Pricing Committee Anouncement. Retrieved April 22, 2015, from 
http://www.eda.mohp.gov.eg/Articles.aspx?id=133 
Caridi, M., Moretto, A., Perego, A., & Tumino, A. (2014). The benefits of supply 
chain visibility: A value assessment model. International Journal of 
 63 
Production Economics, 151(0), 1–19. doi: 
http://dx.doi.org/10.1016/j.ijpe.2013.12.025 
Chad Autry, & Sanders, N. (2011). Supply Chain Security: A Dynamic Capabilities 
Approach. Ft. Lauderdale, FL, USA: J. Ross Publishing Inc. 
Chae, S., & Heidhues, P. (2004). Buyers' Alliances for Bargaining Power. Rochester: 
Social Science Research Network. 
Chopra, S., & Meindl, P. (2007). Supply chain management: strategy, planning, and 
operation. Upper Saddle River, N.J.: Pearson Prentice Hall. 
Chopra, S., & Sodhi, M. S. (2004). Managing Risk to Avoid Supply-Chain 
Breakdown. MIT Sloan Management Review, 46(1), 53–61.  
Christopher, M. (2002). Supply Chain Risk and Vulnerability. The Newsletter for the 
Cranfield Centre for Logistics and Transportation. 
Christopher, M. (2003). Creating Resilient Supply Chains: A Practical Guide (pp. 1–
100): Centre for Logistics and Supply Chain Management at the Cranfield 
School of Management. 
Christopher, M. (2011). Logistics and Supply Chain Management: Financial Times 
Prentice Hall. 
Cooper, M. C., Douglas, M. L., & Janus, D. P. (1997). Supply Chain Management: 
More Than a New Name for Logistics. The International Journal of Logistics 
Management, 8(1), 1–14. doi: http://dx.doi.org/10.1108/09574099710805556 
Costantino, N., & Pellegrino, R. (2010). Choosing between single and multiple 
sourcing based on supplier default risk: A real options approach. Journal of 
Purchasing and Supply Management, 16(1), 27–40. doi: 
http://dx.doi.org/10.1016/j.pursup.2009.08.001 
Cox Jr, L. A. (2008). What's Wrong with Risk Matrices? Risk Analysis: An 
International Journal, 28(2), 497–512.  
CQI, T. C. Q. I. (2010). A Guide to Supply Chain Risk Management for the 
Pharmaceutical and Medical Device Industries and their Suppliers Risk 
Management Toolbox (Vol. V.1.0). London, UK. 
Craighead, C. W., Blackhurst, J., Rungtusanatham, M. J., & Handfield, R. B. (2007). 
The Severity of Supply Chain Disruptions: Design Characteristics and 
Mitigation Capabilities. Decision Sciences, 38(1), 131–156.  
CSCMP. (2014). CSCMP Supply Chain Management. Retrieved November 20, 2014, 
from http://cscmp.org/about-us/supply-chain-management-definitions 
 64 
Dani, S. (2009). Predicting and Managing Supply Chain Risks. In G. Zsidisin & B. 
Ritchie (Eds.), Supply Chain Risk (Vol. 124, pp. 53–66): Springer US. 
Dul, J., & Hak, T. (2008). Case Study Methodology in Business Research: 
Butterworth-Heinemann/Elsevier. 
Elzarka, S. M. (2013). Supply chain risk management: the lessons learned from the 
Egyptian revolution 2011. International Journal of Logistics Research and 
Applications, 16(6), 482–492. doi: 
http://dx.doi.org/10.1080/13675567.2013.846307 
Enyinda, C., Mba, C., Manu, F., & Adase, S. (2009). Quantification of Risk 
Mitigation in Ghanaian Pharmaceutical Industry Supply Chain. Paper 
presented at the 10th Annual Conference Repositioning African Business and 
Development for the 21st Century.  
Faisal, M. N. (2009). Prioritization of Risks in Supply Chains. In T. Wu & J. 
Blackhurst (Eds.), Managing Supply Chain Risk and Vulnerability (pp. 41–
66): Springer London. 
Faten, K. (February 9, 2015). The Egyptian Minister of Health declares Amendment 
decision to medicine pricing. Dostor. Retrieved from 
http://www.dostor.org/768958 
Felea, M., & Albastroiu, I. (2013). An Introduction to Supply Chain Risk 
Management: Definitions and Theories Perspective. Valahian Journal of 
Economic Studies, 4(3), 57–64. 
Gostin, L. O., & Buckley, G. J. (2013). Countering the Problem of Falsified and 
Substandard Drugs. Washington, DC: The National Academies Press  
Guba, E. G. (1981). ERIC/ECTJ Annual Review Paper. Educational Communication 
and Technology, 29(2), 75–91.  
Hancock, D. R., & Algozzine, B. (2006). Doing Case Study Research: A Practical 
Guide for Beginning Researchers: Teachers College Press. 
Handfield, R. (2008). Consumers of Supply Chain Risk Data. In R. Handfield & K. P. 
McCormack (Eds.), Supply Chain Risk Management: Minimizing Disruptions 
in Global Sourcing (pp. 1–26): Taylor & Francis. 
Handfield, R., Blackhurst, J., Elkins, D., & Craighead, W. C. (2008). A Framework 
for Reducing the Impact of Disruptions to the Supply Chain: Observations frm 
Multiple Executives. In R. Handfield & K. P. McCormack (Eds.), Supply 
 65 
Chain Risk Management: Minimizing Disruptions in Global Sourcing (pp. 
43,44): Taylor & Francis. 
Hopkin, P. (2013). Risk Management: Kogan Page, Limited. 
Jaberidoost, M., Shekoufeh, N., Akbar, A., & Rassoul, D. (2013). Pharmaceutical 
supply chain risks: a systematic review. DARU Journal of Pharmaceutical 
Sciences, 21, 1–7.  
Jain, V., & Benyoucef, L. (2008). Managing long supply chain networks: some 
emerging issues and challenges. Journal of Manufacturing Technology 
Management, 19(4), 469–496. doi: 
http://dx.doi.org/10.1108/17410380810869923 
Jüttner, U. (2005). Supply chain risk management. International Journal of Logistics 
Management, 16(1), 120–141. doi: 
http://dx.doi.org/10.1108/09574090510617385 
Jüttner, U., Peck, H., & Christopher, M. (2003). Supply chain risk management: 
outlining an agenda for future research. International Journal of Logistics 
Research and Applications, 6(4), 197–210. doi: 
http://dx.doi.org/10.1080/13675560310001627016 
Kahneman, D., & Tversky, A. (1982). Subjective probability: A judgement of 
representativeness. In D. Kahneman, P. Slovic, & A. Tversky (Eds.), 
Judgment under uncertainty: heuristics and biases (pp. 32–47). Cambridge: 
Cambridge University Press. 
Kamath, J. K., Kamath, K., Azaruddin, M., & Subrahmanyam, E. (2012). Evaluation 
of different types of risks in pharmaceutical supply-chain. American Journal 
of PharmTech Research, 2, 280–287.  
Kersten, W., Boger, M., Hohrath, P., & Spath, H. (2006). Managing Risks in Supply 
Chains: How to Build Reliable Collaboration in Logistics. In T. Blecker & W. 
Kersten (Eds.), (pp. 3–17): Erich Schmidt. 
Kothari, C. R. (2004). Research methodology methods & techniques. from 
http://public.eblib.com/choice/publicfullrecord.aspx?p=431524 
KPMG. (2009). Risk Management in the Pharmaceuticals and Life Sciences Industry: 
An Economist Intelligence Unit research program. 
Kritchanchai, D. (2012). A Framework for Healthcare Supply Chain Improvement in 
Thailand Improvement in Thailand. Operations and Supply Chain 
Management: An International Journal, 5(2), 103–113.  
 66 
Lee, H. L. (2004). The triple-A supply chain. Harvard Business Review, 82(10), 102–
113.  
Mentzer, J. T., DeWitt, W., Keebler, J. S., Min, S., & et al. (2001). Defining supply 
chain management. Journal of Business Logistics, 22(2), 1–26.  
Mieghem, J. A. (2011). Risk Management and Operational Hedging: An Overview. In 
D. Paulson, P. Kouvelis, & R. Li (Eds.), Wiley Handbooks in Operations 
Research and Management Science: Handbook of Integrated Risk 
Management in Global Supply Chains (pp. 13–24). Hoboken, NJ, USA: John 
Wiley & Sons. 
Mollah, H., Long, M., & Baseman, H. (2013). Wiley Series in Biotechnology and 
Bioengineering, Volume 4 : Risk Management Applications in Pharmaceutical 
and Biopharmaceutical Manufacturing. Somerset, NJ, USA: John Wiley & 
Sons. 
Nollet, J., & Beaulieu, M. (2003). The development of group purchasing: an empirical 
study in the healthcare sector. Journal of Purchasing and Supply Management, 
9(1), 3–10. doi: http://dx.doi.org/10.1016/S0969-7012(02)00034-5 
Norrman, A., & Jansson, U. (2004). Ericsson's proactive supply chain risk 
management approach after a serious sub‐supplier accident. International 
Journal of Physical Distribution & Logistics Management, 34(5), 434–456. 
doi: http://dx.doi.org/10.1108/09600030410545463 
OECD. (2008). The Economic Impact of Counterfeiting and Piracy: OECD 
Publishing. 
OECD. (2014). Business Climate Review of Egypt: Investment Policies and Public-
Private Partnerships Private Sector Development Project Insights (pp. 1–19). 
Paulson, D., Kouvelis, P., & Li, R. (2011). Wiley Handbooks in Operations Research 
and Management Science: Handbook of Integrated Risk Management in 
Global Supply Chains. Hoboken, NJ, USA: John Wiley & Sons. 
Pedroso, M. C., & Nakano, D. (2009). Knowledge and information flows in supply 
chains: A study on pharmaceutical companies. International Journal of 
Production Economics, 122(1), 376–384. doi: 
http://dx.doi.org/10.1016/j.ijpe.2009.06.012 
Pentti, R. (2007). Arteology, the science of products and professions. Retrieved 
March 23, 2015, from http://www2.uiah.fi/projects/metodi/178.htm 
 67 
Pharco. (2014). About Pharco. Retrieved March 23, 2015, from 
http://www.pharco.org/about.aspx 
Rao, S., & Goldsby, T. J. (2009). Supply chain risks: a review and typology. 
International Journal of Logistics Management, 20(1), 97–123. doi: 
http://dx.doi.org/10.1108/09574090910954864 
Ritchie, B., & Brindley, C. (2009). Effective Management of Supply Chains: Risks 
and Performance. In T. Wu & J. Blackhurst (Eds.), Managing Supply Chain 
Risk and Vulnerability (pp. 9–28): Springer London. 
Schotanus, F., & Telgen, J. (2007). Developing a typology of organisational forms of 
cooperative purchasing. Journal of Purchasing and Supply Management, 
13(1), 53–68. doi: http://dx.doi.org/10.1016/j.pursup.2007.03.002 
Sen, A. (2000). The discipline of cost-benefit analysis. The Journal of Legal Studies, 
29(S2), 931–952.  
Shah, N. (2004). Pharmaceutical supply chains: key issues and strategies for 
optimisation. Computers & Chemical Engineering, 28(6–7), 929–941. doi: 
http://dx.doi.org/10.1016/j.compchemeng.2003.09.022 
Silbermayr, L., & Minner, S. (2014). A multiple sourcing inventory model under 
disruption risk. International Journal of Production Economics, 149(0), 37–
46. doi: http://dx.doi.org/10.1016/j.ijpe.2013.03.025 
Silverman, D. (1993). Interpreting qualitative data: methods for analysing talk, text 
and interaction: Sage. 
Skipper, J. B., Hanna, J. B., & Cegielski, C. G. (2009). Supply Chain Contingency 
Planning and Firm Adoption: An Initial Look at Differentiating the 
Innovators. Transportation Journal, 48(2), 40–62. doi: 
10.1108/09600030610642913 
Sodhi, M. S., & Tang, C. S. (2009). Managing Supply Chain Disruptions via Time-
Based Risk Management. In T. Wu & J. Blackhurst (Eds.), Managing Supply 
Chain Risk and Vulnerability (pp. 29–40): Springer London. 
Sodhi, M. S., & Tang, C. S. (2012). Managing supply chain risk (Vol. 172): Springer 
Science & Business Media. 
Sollish, F., & Semanik, J. (2005). The Purchasing and Supply Manager's Guide To 
The C.P.M. Exam: SYBEX Inc. 
 68 
Spekman, R. E., & Davis, E. W. (2004). Risky business: expanding the discussion on 
risk and the extended enterprise. International Journal of Physical 
Distribution & Logistics Management, 34(5), 414–433.  
Stock, J. R., & Boyer, S. L. (2009). Developing a consensus definition of supply chain 
management: a qualitative study. International Journal of Physical 
Distribution & Logistics Management, 39(8), 690–711. doi: 
http://dx.doi.org/10.1108/09600030910996323 
Tang, C. S. (2006). Robust strategies for mitigating supply chain disruptions. 
International Journal of Logistics Research and Applications, 9(1), 33–45. 
doi: http://dx.doi.org/10.1080/13675560500405584 
Tella, E., & Virolainen, V.-M. (2005). Motives behind purchasing consortia. 
International Journal of Production Economics, 93–94(0), 161–168. doi: 
http://dx.doi.org/10.1016/j.ijpe.2004.06.014 
Waters, D. (2007). Supply Chain Risk Management–Vulnerability and Resilience in 
Logistics: Kogan Page Publishers. 
Watkins, S. (2012). The Pharmaceutical Market in Egypt 
Macroeconomic environment, market analysis, key trends and growth opportunities 
SCRIP Insights (pp. 11–70). 
Yin, R. (1994). Case Study Research, Design andMethods. London: Sage 
Publications. 
Yu, Z., Hong, Y., & Cheng, T. C. E. (2001). Benefits of information sharing with 
supply chain partnerships. Industrial Management & Data Systems, 101(3/4), 
114–119.  
Zsidisin, G. A., Panelli, A., & Upton, R. (2000). Purchasing organization involvement 
in risk assessments, contingency plans, and risk management: an exploratory 
study. Supply Chain Management, 5(4), 187.  
 
 
 
 
 
 
 
 69 
Appendix 1—Interview Protocol 
INTERVIEW QUESTIONS 
- General information (name, department, experience, roles) 
- Can you give a description of your company’s supply chain? 
- What are the supply chain problems that you face as a pharmaceutical company 
operating in Egypt? 
- What are the potential threats/risks in your supply chain that may prevent your 
company from achieving its goals? 
- How does the company deal with its supply chain risks? 
PARTICIPANTS AND DATE OF INTERVIEWS 
 
  
RISK RANKING/PRIORITIZING 
 
Identified Risks 
Risk Analysis Risk Factor 
Impact (I) 
(score 1–5) 
Likelihood (L) 
(Score 1–3) 
Score 
I * L 
Regulatory Risk    
Risk related to Foreign Currency and Loans’ 
Interest Rate  
  
 
Supplier Risk    
Counterfeit Risk    
Lack of SC Transparency    
Strikes    
Political Instability    
 
Interview Date Interviewee Interview Type 
January 5, 2015 Sales Manager Personal Interview 
January 5, 2015 Returned Products Supervisor Personal Interview 
January 12, 2015 Quality Assurance Manager Personal Interview 
January 26, 2015 Import & Export Manager Telephone Interview 
February 2, 2015 Development Sector Head Telephone Interview 
February 5, 2015 Quality Assurance Manager Telephone Interview 
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Appendix 2— Flow Chart on Inspection of Imported Raw Materials  
General Directorate of Pharmaceutical Inspection Department of Imported Raw Materials Inspection 
 
 
Source: http://www.eda.mohp.gov.eg/Files/383_FlowChart_Imported_Row_Materials.pdf   (Last Accessed: February, 22 2015) 
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Appendix 3—Egypt’s Country Political Risk 
Source: http://www3.ambest.com/ratings/cr/reports/Egypt.pdf (Last Accessed: April, 25, 2015) 
